



Belgian Cancer Registry

CANCER FACT SHEET 2022

LUNG CANCER

ICD-10 C34



CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ($=200 \times 1.05$) and 255/100,000 over 5 years ($=200 \times (1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. For lung cancer, stage IV means the cancer has spread to other organs. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

SCLC: Small cell lung cancer.

NSCLC: Non-small cell lung cancer.

- **SCC:** Squamous cell carcinoma, a type of non-small cell lung cancer.
- **ADC:** Adenocarcinoma, a type of non-small cell lung cancer.
- **LCC:** Large cell undifferentiated carcinoma, a type of non-small cell lung cancer.



1. CANCER INCIDENCE	5
1.1. Lung cancer incidence: by region.....	5
1.1.1. Lung cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022.....	5
1.2. Lung cancer incidence: by tumour stage	7
1.2.2. Lung cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	7
1.2.3. Lung cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022	8
1.2.4. Lung cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	8
1.2.5. Lung cancer incidence by histological type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	9
2. CANCER INCIDENCE TRENDS	11
2.1. Lung cancer incidence trends: by region	11
2.1.1. Lung cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022	11
2.1.2. Lung cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	13
2.2. Lung cancer incidence trends: by tumour stage	15
2.2.3. Lung cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards	15
2.3. Lung cancer incidence trends: by age group	17
2.3.4. Lung cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	17
2.3.5. Lung cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	18
3. CANCER PREVALENCE	19
3.1. Lung cancer prevalence: by region	19
3.1.1. Lung cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022.....	19
4. CANCER SURVIVAL.....	20
4.1. Lung cancer survival: by region.....	20
4.1.1. Lung cancer survival by region, sex and age group: number at risk and net survival probabilities, 2013-2022	20
4.2. Lung cancer survival: by histological type and tumour stage	22
4.2.2. Lung cancer survival by histological type, clinical stage (cStage) and sex: number at risk and net survival probabilities, 2013-2022	22
4.2.3. Lung cancer survival by histological type, pathological stage (pStage) and sex: number at risk and net survival probabilities, 2013-2022.....	27
4.2.4. Lung cancer survival by histological type, stage and sex: number at risk and net survival probabilities, 2013-2022.....	32

5. CANCER SURVIVAL TRENDS.....	37
5.1. Lung cancer survival trends: by tumour stage	37
5.1.1. Lung cancer survival trends by stage and sex: number at risk and net survival probabilities, 2008-2022...	37
6. CANCER MORTALITY	39
6.1. Lung cancer mortality: by region	39
6.1.1. Lung cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021	39
7. CANCER MORTALITY TRENDS.....	41
7.1. Lung cancer mortality trends: by region	41
7.1.1. Lung cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021	41
7.1.2. Lung cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021	43

1. CANCER INCIDENCE



1.1. Lung cancer incidence: by region

1.1.1. Lung cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Males																						
Belgium	1	0	0	0	0	0	5	16	43	73	194	396	729	1,055	1,135	975	642	317	91	5	5,677	106.1
	[0.3]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.3]	[4.3]	[11.3]	[19.5]	[49.0]	[98.0]	[197.5]	[337.7]	[429.9]	[512.5]	[507.1]	[404.1]	[303.1]	[85.5]	[99.4]	(103.3; 108.9)
Brussels	0	0	0	0	0	0	0	1	3	6	28	46	63	55	64	54	25	19	4	1	369	95.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.1]	[6.5]	[13.8]	[69.3]	[132.6]	[225.3]	[259.8]	[387.4]	[443.6]	[309.6]	[373.5]	[184.5]	[187.6]	[61.5]	(85.2; 105.1)
Flanders	0	0	0	0	0	0	3	6	20	32	84	185	376	598	660	629	433	229	62	4	3,321	99.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.4]	[2.9]	[9.2]	[15.2]	[36.3]	[75.7]	[167.2]	[311.4]	[408.3]	[509.5]	[518.2]	[436.5]	[311.1]	[105.8]	[100.1]	(96.2; 103.0)
Wallonia	1	0	0	0	0	0	2	9	20	35	82	165	290	402	411	292	184	69	25	0	1,987	120.4
	[1.1]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.7]	[7.8]	[17.3]	[29.0]	[65.9]	[131.9]	[249.6]	[405.0]	[478.9]	[534.7]	[526.3]	[330.3]	[315.2]	[0.0]	[110.9]	(115.0; 125.7)
Females																						
Belgium	0	0	0	1	1	2	9	20	31	86	183	352	558	758	719	516	315	126	50	6	3,733	60.8
	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[0.6]	[2.3]	[5.4]	[8.2]	[23.4]	[47.3]	[88.3]	[148.1]	[227.9]	[243.5]	[223.3]	[176.8]	[93.6]	[72.1]	[29.2]	[63.5]	(58.9; 62.8)
Brussels	0	0	0	0	0	0	2	2	4	6	13	16	28	46	48	40	25	12	7	1	250	51.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[3.8]	[4.2]	[8.9]	[14.9]	[34.9]	[47.4]	[94.1]	[184.7]	[225.1]	[232.0]	[191.9]	[119.3]	[121.3]	[48.5]	[40.2]	(45.3; 58.2)

Region	N [CR]																				All ages	ESR2013 (95%CI)
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		
Flanders	0	0	0	1	0	2	5	16	15	38	85	198	299	431	382	287	194	73	33	3	2,062	55.9
	[0.0]	[0.0]	[0.0]	[0.6]	[0.0]	[1.0]	[2.4]	[7.6]	[6.9]	[18.4]	[37.7]	[83.1]	[133.2]	[218.0]	[220.0]	[200.7]	[173.2]	[85.8]	[77.5]	[24.8]	[61.0]	(53.5; 58.3)
Wallonia	0	0	0	0	1	0	2	2	12	42	85	138	231	281	289	189	96	41	10	2	1,421	72.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[1.7]	[1.7]	[10.3]	[35.0]	[68.4]	[108.7]	[188.7]	[255.5]	[288.2]	[266.6]	[180.5]	[103.8]	[47.5]	[31.4]	[76.0]	(68.5; 76.0)

1.2. Lung cancer incidence: by tumour stage

1.2.2. Lung cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

cStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	141 [4.2]	690 [73.0]	474 [109.9]	1,305 [22.9]	24.5 (23.1; 25.8)	186 [5.6]	541 [53.9]	259 [40.9]	986 [16.8]	16.2 (15.2; 17.2)
II	37 [1.1]	199 [21.0]	170 [39.4]	406 [7.1]	7.7 (6.9; 8.4)	38 [1.2]	128 [12.7]	84 [13.3]	250 [4.3]	4.1 (3.6; 4.6)
III	137 [4.1]	553 [58.5]	375 [87.0]	1,065 [18.7]	19.8 (18.6; 21.0)	100 [3.0]	343 [34.1]	162 [25.6]	605 [10.3]	9.9 (9.1; 10.7)
IV	376 [11.2]	1,328 [140.5]	888 [206.0]	2,592 [45.4]	48.3 (46.4; 50.1)	324 [9.8]	916 [91.2]	444 [70.0]	1,684 [28.7]	27.3 (26.0; 28.6)
X/NA	36 [1.1]	149 [15.8]	123 [28.5]	309 [5.4]	5.8 (5.2; 6.5)	37 [1.1]	107 [10.7]	64 [10.1]	208 [3.5]	3.4 (2.9; 3.9)

1.2.3. Lung cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

pStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	105 [3.1]	387 [40.9]	135 [31.3]	627 [11.0]	11.4 (10.5; 12.3)	156 [4.7]	325 [32.4]	80 [12.6]	561 [9.5]	9.4 (8.6; 10.2)
II	29 [0.9]	138 [14.6]	57 [13.2]	224 [3.9]	4.1 (3.6; 4.6)	36 [1.1]	104 [10.4]	27 [4.3]	167 [2.8]	2.8 (2.4; 3.2)
III	24 [0.7]	76 [8.0]	42 [9.7]	142 [2.5]	2.6 (2.2; 3.1)	26 [0.8]	53 [5.3]	16 [2.5]	95 [1.6]	1.6 (1.3; 1.9)
IV	64 [1.9]	185 [19.6]	125 [29.0]	374 [6.6]	7.0 (6.2; 7.7)	52 [1.6]	123 [12.2]	53 [8.4]	228 [3.9]	3.7 (3.2; 4.2)
X/NA	505 [15.1]	2,133 [225.6]	1,671 [387.6]	4,310 [75.5]	81.0 (78.6; 83.4)	415 [12.6]	1,430 [142.4]	837 [132.0]	2,682 [45.7]	43.4 (41.7; 45.0)

1.2.4. Lung cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	140 [4.2]	675 [71.4]	473 [109.7]	1,288 [22.6]	24.2 (22.8; 25.5)	183 [5.6]	530 [52.8]	257 [40.5]	970 [16.5]	15.9 (14.9; 16.9)
II	43 [1.3]	232 [24.5]	168 [39.0]	443 [7.8]	8.3 (7.5; 9.1)	46 [1.4]	154 [15.3]	92 [14.5]	292 [5.0]	4.8 (4.2; 5.3)
III	137 [4.1]	564 [59.7]	391 [90.7]	1,092 [19.1]	20.4 (19.2; 21.6)	108 [3.3]	356 [35.4]	169 [26.7]	633 [10.8]	10.3 (9.5; 11.2)
IV	381 [11.4]	1,342 [141.9]	896 [207.8]	2,619 [45.9]	48.8 (46.9; 50.6)	324 [9.8]	922 [91.8]	449 [70.8]	1,695 [28.9]	27.5 (26.2; 28.8)
X/NA	26 [0.8]	106 [11.2]	102 [23.7]	235 [4.1]	4.5 (3.9; 5.1)	24 [0.7]	73 [7.3]	46 [7.3]	143 [2.4]	2.3 (1.9; 2.7)

1.2.5. Lung cancer incidence by histological type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Histological types	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
SCLC	I	5 [0.1]	16 [1.7]	7 [1.6]	28 [0.5]	0.5 (0.3; 0.7)	1 [0.0]	10 [1.0]	7 [1.1]	18 [0.3]	0.3 (0.2; 0.4)
	II	2 [0.1]	7 [0.7]	6 [1.4]	15 [0.3]	0.3 (0.1; 0.4)	6 [0.2]	16 [1.6]	4 [0.6]	26 [0.4]	0.4 (0.3; 0.6)
	III	16 [0.5]	87 [9.2]	40 [9.3]	143 [2.5]	2.6 (2.2; 3.0)	22 [0.7]	69 [6.9]	27 [4.3]	118 [2.0]	1.9 (1.6; 2.3)
	IV	64 [1.9]	293 [31.0]	142 [32.9]	499 [8.7]	9.2 (8.4; 10.0)	53 [1.6]	207 [20.6]	66 [10.4]	326 [5.5]	5.4 (4.8; 5.9)
	X/NA	3 [0.1]	13 [1.4]	14 [3.2]	30 [0.5]	0.6 (0.4; 0.8)	2 [0.1]	14 [1.4]	8 [1.3]	24 [0.4]	0.4 (0.2; 0.5)
NSCLC	I	115 [3.4]	515 [54.5]	281 [65.2]	911 [16.0]	16.9 (15.8; 18.0)	169 [5.1]	410 [40.8]	161 [25.4]	740 [12.6]	12.3 (11.4; 13.2)
	II	39 [1.2]	207 [21.9]	126 [29.2]	372 [6.5]	6.9 (6.2; 7.6)	39 [1.2]	127 [12.6]	69 [10.9]	235 [4.0]	3.9 (3.4; 4.4)
	III	119 [3.6]	457 [48.3]	297 [68.9]	873 [15.3]	16.2 (15.2; 17.3)	85 [2.6]	277 [27.6]	121 [19.1]	483 [8.2]	7.9 (7.2; 8.6)
	IV	310 [9.3]	1,005 [106.3]	615 [142.6]	1,930 [33.8]	35.8 (34.2; 37.4)	268 [8.1]	680 [67.7]	330 [52.1]	1,278 [21.8]	20.8 (19.7; 22.0)
	X/NA	20 [0.6]	77 [8.1]	72 [16.7]	169 [3.0]	3.2 (2.7; 3.7)	15 [0.5]	45 [4.5]	34 [5.4]	94 [1.6]	1.5 (1.2; 1.8)
SCC	I	17 [0.5]	174 [18.4]	110 [25.5]	301 [5.3]	5.7 (5.0; 6.3)	6 [0.2]	71 [7.1]	40 [6.3]	117 [2.0]	1.9 (1.6; 2.3)
	II	12 [0.4]	94 [9.9]	64 [14.8]	170 [3.0]	3.2 (2.7; 3.7)	6 [0.2]	34 [3.4]	25 [3.9]	65 [1.1]	1.1 (0.8; 1.3)
	III	49 [1.5]	234 [24.7]	175 [40.6]	458 [8.0]	8.6 (7.8; 9.4)	15 [0.5]	88 [8.8]	42 [6.6]	145 [2.5]	2.4 (2.0; 2.8)
	IV	44 [1.3]	280 [29.6]	171 [39.7]	495 [8.7]	9.2 (8.4; 10.0)	13 [0.4]	92 [9.2]	57 [9.0]	162 [2.8]	2.6 (2.2; 3.0)
	X/NA	3 [0.1]	28 [3.0]	33 [7.7]	64 [1.1]	1.2 (0.9; 1.5)	0 [0.0]	9 [0.9]	8 [1.3]	17 [0.3]	0.3 (0.1; 0.4)
ADC	I	87 [2.6]	305 [32.3]	151 [35.0]	543 [9.5]	10.0 (9.1; 10.8)	126 [3.8]	287 [28.6]	96 [15.1]	509 [8.7]	8.4 (7.7; 9.2)
	II	23 [0.7]	91 [9.6]	50 [11.6]	164 [2.9]	3.0 (2.6; 3.5)	23 [0.7]	73 [7.3]	34 [5.4]	130 [2.2]	2.1 (1.8; 2.5)
	III	61 [1.8]	177 [18.7]	101 [23.4]	339 [5.9]	6.3 (5.6; 6.9)	61 [1.9]	165 [16.4]	67 [10.6]	293 [5.0]	4.8 (4.3; 5.4)
	IV	236 [7.0]	618 [65.4]	382 [88.6]	1,236 [21.7]	22.9 (21.6; 24.2)	233 [7.1]	520 [51.8]	245 [38.7]	998 [17.0]	16.3 (15.3; 17.3)
	X/NA	13 [0.4]	40 [4.2]	31 [7.2]	84 [1.5]	1.6 (1.2; 1.9)	11 [0.3]	30 [3.0]	24 [3.8]	65 [1.1]	1.0 (0.8; 1.3)
LCC	I	0 [0.0]	3 [0.3]	2 [0.5]	5 [0.1]	0.1 (0.0; 0.2)	2 [0.1]	2 [0.2]	0 [0.0]	4 [0.1]	0.1 (0.0; 0.1)

Histological types	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
	II	0 [0.0]	2 [0.2]	5 [1.2]	7 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	2 [0.2]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)
	III	4 [0.1]	9 [1.0]	2 [0.5]	15 [0.3]	0.3 (0.1; 0.4)	2 [0.1]	6 [0.6]	1 [0.2]	9 [0.2]	0.2 (0.1; 0.2)
	IV	5 [0.1]	35 [3.7]	21 [4.9]	61 [1.1]	1.1 (0.9; 1.4)	4 [0.1]	13 [1.3]	11 [1.7]	28 [0.5]	0.4 (0.3; 0.6)
	X/NA	2 [0.1]	2 [0.2]	2 [0.5]	6 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
Other NSCLC	I	11 [0.3]	33 [3.5]	18 [4.2]	62 [1.1]	1.2 (0.9; 1.4)	35 [1.1]	50 [5.0]	25 [3.9]	110 [1.9]	1.8 (1.5; 2.2)
	II	4 [0.1]	20 [2.1]	7 [1.6]	31 [0.5]	0.6 (0.4; 0.8)	10 [0.3]	18 [1.8]	10 [1.6]	38 [0.6]	0.6 (0.4; 0.8)
	III	5 [0.1]	37 [3.9]	19 [4.4]	61 [1.1]	1.1 (0.8; 1.4)	7 [0.2]	18 [1.8]	11 [1.7]	36 [0.6]	0.6 (0.4; 0.8)
	IV	25 [0.7]	72 [7.6]	41 [9.5]	138 [2.4]	2.5 (2.1; 3.0)	18 [0.5]	55 [5.5]	17 [2.7]	90 [1.5]	1.5 (1.2; 1.8)
	X/NA	2 [0.1]	7 [0.7]	6 [1.4]	15 [0.3]	0.3 (0.1; 0.4)	4 [0.1]	6 [0.6]	2 [0.3]	12 [0.2]	0.2 (0.1; 0.3)
Other	I	20 [0.6]	144 [15.2]	185 [42.9]	349 [6.1]	6.8 (6.0; 7.5)	13 [0.4]	110 [11.0]	89 [14.0]	212 [3.6]	3.3 (2.9; 3.8)
	II	2 [0.1]	18 [1.9]	36 [8.3]	56 [1.0]	1.1 (0.8; 1.4)	1 [0.0]	11 [1.1]	19 [3.0]	31 [0.5]	0.5 (0.3; 0.6)
	III	2 [0.1]	20 [2.1]	54 [12.5]	76 [1.3]	1.5 (1.2; 1.9)	1 [0.0]	10 [1.0]	21 [3.3]	32 [0.5]	0.5 (0.3; 0.7)
	IV	7 [0.2]	44 [4.7]	139 [32.2]	190 [3.3]	3.8 (3.3; 4.4)	3 [0.1]	35 [3.5]	53 [8.4]	91 [1.5]	1.3 (1.0; 1.6)
	X/NA	3 [0.1]	16 [1.7]	16 [3.7]	36 [0.6]	0.7 (0.5; 0.9)	7 [0.2]	14 [1.4]	4 [0.6]	25 [0.4]	0.4 (0.3; 0.6)

2. CANCER INCIDENCE TRENDS



2.1. Lung cancer incidence trends: by region

2.1.1. Lung cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period			
Belgium	N	5,510	5,412	5,369	5,510	5,482	5,520	5,663	5,659	5,827	5,732	5,810	5,745	5,473	5,632	5,769	5,662	5,581	5,678	5,677				
	CR	108.3	105.9	104.4	106.3	105.0	104.8	106.6	105.4	107.6	105.2	106.1	104.4	98.8	101.1	103.1	100.6	98.6	100.0	99.4				
	ESR2013	135.2	131.5	128.3	128.7	125.9	125.0	127.7	125.6	126.8	123.2	123.0	119.5	112.3	113.7	114.8	110.6	107.0	107.9	106.1	-1.2 (-1.4; -1.1)	2004-2022		
																					-0.7 (-1.1; -0.3)	2004-2012		
																						-1.7 (-2.0; -1.4)	2013-2022	
Brussels	N	402	394	367	353	372	375	458	379	384	390	391	374	404	381	424	382	395	404	369				
	CR	83.7	81.5	74.9	71.1	73.6	72.6	86.9	69.9	69.5	69.4	69.0	65.3	69.7	65.4	72.3	64.5	66.1	67.4	61.5				
	ESR2013	120.4	117.2	108.7	105.5	108.8	108.5	134.6	109.1	105.9	111.2	108.2	102.6	111.7	104.7	112.6	100.8	104.8	105.0	95.2				
																						-0.7 (-1.3; -0.2)	2004-2022	
Flanders	N	3,269	3,187	3,254	3,351	3,286	3,270	3,375	3,370	3,451	3,423	3,449	3,399	3,218	3,274	3,405	3,299	3,271	3,356	3,321				
	CR	110.2	107.0	108.6	111.1	108.1	106.7	109.4	108.2	110.1	108.6	108.9	106.8	100.5	101.6	105.1	101.2	99.7	101.9	100.1				
	ESR2013	133.6	127.6	127.5	128.1	123.4	121.3	124.1	121.5	122.1	119.7	118.6	114.0	106.6	106.5	109.5	104.1	101.0	102.5	99.6				
																						-1.5 (-1.7; -1.3)	2004-2022	
																							-1.1 (-1.5; -0.7)	2004-2014
																							-2.6 (-3.5; -1.7)	2015-2018
																							-1.4 (-2.5; -0.2)	2019-2022
Wallonia	N	1,839	1,831	1,748	1,806	1,824	1,875	1,830	1,910	1,992	1,919	1,970	1,972	1,851	1,977	1,940	1,981	1,915	1,918	1,987				

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
CR	112.1	111.1	105.5	108.3	108.7	111.1	107.6	111.4	115.5	110.6	113.1	112.7	105.4	112.1	109.6	111.6	107.5	107.5	110.9			
ESR2013	142.0	143.2	135.0	135.5	135.2	135.9	132.3	137.9	140.7	132.1	134.7	134.0	122.9	129.7	124.2	125.0	118.9	118.6	120.4	-1.0 (-1.2; -0.7)	2004-2022	
																				-0.5 (-0.9; 0.0)	2004-2014	
																					-1.5 (-2.1; -1.0)	2015-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Lung cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period		
Belgium	N	1,554	1,592	1,704	1,879	1,814	2,080	2,248	2,347	2,368	2,503	2,673	2,673	2,754	2,885	3,121	3,267	3,326	3,526	3,733			
	CR	29.3	29.8	31.7	34.8	33.3	37.9	40.7	42.1	42.1	44.3	47.1	46.9	48.1	50.1	54.0	56.3	57.0	60.3	63.5			
	ESR2013	30.5	31.0	32.8	35.8	34.4	39.0	41.6	43.2	42.9	45.1	47.3	46.8	48.1	49.7	53.1	55.0	55.4	58.3	60.8	3.9 (3.7; 4.2)	2004-2022	
																					5.3 (4.5; 6.1)	2004-2010	
																						3.3 (2.9; 3.6)	2011-2022
Brussels	N	185	163	189	194	170	203	211	223	221	238	222	235	227	239	258	248	241	247	250			
	CR	35.6	31.2	35.7	36.3	31.4	36.8	37.5	38.7	37.7	40.1	37.2	39.0	37.3	39.2	42.1	40.3	38.8	39.8	40.2			
	ESR2013	40.1	36.3	41.6	42.7	37.0	44.1	45.7	48.5	47.8	52.3	47.8	49.7	48.1	50.4	53.5	51.6	50.3	52.2	51.7	1.9 (1.4; 2.4)	2004-2022	
																					3.5 (2.1; 5.0)	2004-2011	
																						1.0 (0.1; 1.8)	2012-2022
Flanders	N	824	864	888	996	977	1,079	1,207	1,258	1,270	1,350	1,425	1,459	1,503	1,559	1,737	1,821	1,853	1,969	2,062			
	CR	27.0	28.2	28.8	32.1	31.3	34.3	38.1	39.4	39.5	41.8	43.9	44.7	45.9	47.3	52.4	54.7	55.3	58.6	61.0			
	ESR2013	27.6	28.4	29.0	32.1	31.3	34.1	37.5	38.9	38.5	40.7	42.2	42.9	43.8	44.8	49.5	50.9	51.5	54.1	55.9	4.2 (3.9; 4.4)	2004-2022	
																					5.1 (4.3; 5.9)	2004-2011	
																					2.8 (1.7; 4.0)	2012-2015	
																					4.0 (3.2; 4.7)	2016-2022	
Wallonia	N	545	565	627	689	667	798	830	866	877	915	1,026	979	1,024	1,087	1,126	1,198	1,232	1,310	1,421			
	CR	31.3	32.3	35.7	39.0	37.5	44.6	46.2	47.8	48.2	50.0	55.9	53.2	55.5	58.8	60.7	64.5	66.1	70.3	76.0			
	ESR2013	33.2	34.4	37.6	40.8	39.2	46.8	48.0	49.7	49.6	51.4	56.8	52.9	55.9	58.6	59.7	63.4	63.9	67.5	72.3	4.1 (3.8; 4.5)	2004-2022	
																					5.8 (4.8; 6.8)	2004-2011	
																					3.1 (2.5; 3.7)	2012-2022	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Lung cancer incidence trends: by tumour stage

2.2.3. Lung cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards

Stage	Males							Females							
	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
I	N	1,046	1,199	1,125	1,216	1,288			693	760	781	934	970		
	CR	18.7	21.3	19.9	21.4	22.6			12.0	13.1	13.4	16.0	16.5		
	ESR2013	20.8	23.4	21.6	23.2	24.2	1.8 (1.3; 2.3)	2004-2022	12.0	12.9	13.0	15.6	15.9	8.4 (7.9; 8.9)	2004-2022
													11.4 (9.4; 13.3)	2004-2009	
													7.3 (6.7; 7.9)	2010-2022	
II	N	451	464	406	443	443			216	230	227	230	292		
	CR	8.1	8.2	7.2	7.8	7.8			3.7	4.0	3.9	3.9	5.0		
	ESR2013	9.0	9.1	7.9	8.4	8.3	0.9 (0.2; 1.5)	2004-2022	3.7	3.9	3.8	3.8	4.8	7.1 (5.9; 8.4)	2004-2022
						5.1 (3.6; 6.6)	2004-2013						11.7 (8.0; 15.5)	2004-2011	
						-3.2 (-4.6; -1.8)	2014-2022						4.4 (2.3; 6.5)	2012-2022	
III	N	1,259	1,144	1,094	1,109	1,092			592	620	579	606	633		
	CR	22.5	20.3	19.3	19.5	19.1			10.2	10.7	9.9	10.4	10.8		
	ESR2013	25.0	22.3	20.8	21.1	20.4	-1.1 (-1.5; -0.6)	2004-2022	10.1	10.5	9.6	10.0	10.3	4.2 (3.7; 4.8)	2004-2022
						0.6 (-0.3; 1.6)	2004-2013						6.6 (5.1; 8.1)	2004-2012	
						-2.7 (-3.7; -1.8)	2014-2022						2.4 (1.3; 3.5)	2013-2022	
IV	N	2,708	2,648	2,742	2,784	2,619			1,471	1,532	1,615	1,674	1,695		
	CR	48.4	47.0	48.4	49.0	45.9			25.5	26.4	27.7	28.6	28.9		
	ESR2013	53.9	51.6	52.6	52.9	48.8	1.6 (1.2; 1.9)	2004-2022	24.8	25.7	26.9	27.6	27.5	6.1 (5.6; 6.6)	2004-2022
						3.2 (2.5; 4.0)	2004-2014						8.2 (7.2; 9.2)	2004-2014	
						-0.5 (-1.4; 0.4)	2015-2022						3.6 (2.3; 4.8)	2015-2022	

Stage	Males							Females						
	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
X/NA N	305	207	214	126	235			149	125	124	82	143		
CR	5.4	3.7	3.8	2.2	4.1			2.6	2.2	2.1	1.4	2.4		
ESR2013	6.2	4.1	4.1	2.4	4.5	-14.5 (-15.8; -13.1)	2004-2022	2.5	2.1	2.0	1.3	2.3	-10.3 (-11.7; -8.9)	2004-2022
						-10.8 (-14.2; -7.2)	2004-2012						-4.4 (-9.3; 0.9)	2004-2010
						-17.4 (-19.9; -14.8)	2013-2022						-13.1 (-15.2; -11.0)	2011-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Lung cancer incidence trends: by age group

2.3.4. Lung cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
15-59	N	1,171	1,139	1,158	1,158	1,174	1,171	1,084	1,090	1,105	1,031	1,013	944	896	861	855	834	816	781	727		
	CR	36.7	35.5	35.9	35.8	36.1	35.8	33.0	33.0	33.3	31.0	30.5	28.4	26.9	25.8	25.6	25.0	24.4	23.4	21.7		
	ESR2013	39.7	37.7	37.7	37.4	37.7	37.3	34.1	33.8	33.8	31.3	30.4	28.0	26.3	25.2	24.9	24.2	23.6	22.6	21.1	-3.3 (-3.5; -3.1)	2004-2022
60-74	N	2,707	2,646	2,547	2,654	2,572	2,579	2,659	2,663	2,779	2,735	2,815	2,862	2,732	2,894	2,974	2,941	2,909	2,896	2,919		
	CR	397.8	386.3	370.8	379.2	360.9	354.7	358.7	352.3	361.2	349.1	353.3	352.2	328.1	337.8	338.2	327.4	317.3	309.9	308.7		
	ESR2013	395.5	385.0	370.7	382.2	367.0	362.5	367.6	362.8	371.0	359.5	363.5	361.7	338.2	346.4	344.9	332.9	322.9	315.0	314.7	-1.2 (-1.3; -1.0)	2004-2022
75+	N	1,632	1,627	1,663	1,698	1,734	1,770	1,920	1,906	1,942	1,966	1,981	1,937	1,845	1,876	1,940	1,887	1,856	1,999	2,030		
	CR	556.7	537.5	529.5	521.2	514.9	512.2	542.3	527.7	526.1	522.8	516.6	494.8	467.4	475.2	488.4	467.0	448.8	480.4	470.8		
	ESR2013	519.5	510.2	500.6	485.6	481.4	482.2	523.0	510.9	508.9	506.0	502.2	481.9	456.3	464.0	481.5	460.9	443.6	474.4	464.8	-0.6 (-0.9; -0.2)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3.5. Lung cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period		
15-59	N	540	547	600	622	588	709	734	690	727	720	694	681	705	684	644	721	640	646	685			
	CR	17.2	17.4	18.9	19.5	18.4	22.0	22.7	21.2	22.2	22.0	21.1	20.7	21.4	20.8	19.6	21.9	19.5	19.6	20.8			
	ESR2013	18.1	18.1	19.5	20.0	18.8	22.5	23.0	21.3	22.2	21.8	20.9	20.2	20.9	20.2	19.0	21.2	18.8	19.0	20.3	0.4 (0.0; 0.8)	2004-2022	
																					3.8 (2.4; 5.2)	2004-2010	
																						-1.2 (-1.8; -0.6)	2011-2022
60-74	N	627	641	688	784	796	875	955	1,074	1,058	1,190	1,282	1,289	1,363	1,495	1,669	1,696	1,846	1,924	2,035			
	CR	80.9	82.7	89.1	100.5	101.0	109.4	117.9	130.5	126.8	140.5	149.4	147.8	152.8	162.9	177.5	176.9	188.9	193.5	202.6			
	ESR2013	80.9	83.0	88.7	100.4	101.3	110.4	118.3	131.7	127.5	141.4	149.8	148.1	154.2	163.8	178.3	177.6	189.5	194.3	203.6	5.4 (5.1; 5.6)	2004-2022	
																					6.7 (6.1; 7.4)	2004-2012	
																						4.3 (3.8; 4.8)	2013-2022
75+	N	387	404	415	473	430	496	559	583	583	592	697	703	686	704	807	850	840	956	1,013			
	CR	74.4	76.1	76.2	84.9	75.5	85.8	95.3	98.3	97.2	98.0	114.2	113.9	111.3	114.9	132.0	138.4	135.4	154.5	159.8			
	ESR2013	73.2	74.8	75.5	84.1	73.9	84.9	95.3	99.3	98.5	100.1	115.7	116.4	115.6	120.7	140.0	147.9	145.6	167.7	171.0	5.0 (4.5; 5.5)	2004-2022	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3. CANCER PREVALENCE



3.1. Lung cancer prevalence: by region

3.1.1. Lung cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022

Region		Males				Females			
		1-year	5-year	10-year	15-year	1-year	5-year	10-year	15-year
Belgium	N	3,879	10,948	14,282	15,775	2,798	8,161	10,839	11,978
	CR	67.3	190.0	247.9	274	47.1	137.5	182.6	202
	ESR2013	70.8	200.2	261.9	289.8	45.2	131.4	174.1	192.0
Brussels	N	269	768	986	1,071	190	587	795	891
	CR	44.2	126.3	162.1	176.1	30.0	92.7	125.6	140.8
	ESR2013	67.9	194.0	250.9	272.6	38.9	120.5	163.2	182.9
Flanders	N	2,252	6,427	8,432	9,328	1,551	4,520	5,989	6,592
	CR	67.2	191.7	251.5	278.3	45.3	132.1	175.0	192.6
	ESR2013	66.2	188.9	248.2	274.8	41.7	121.0	159.9	175.6
Wallonia	N	1,358	3,753	4,864	5,376	1,057	3,054	4,055	4,495
	CR	75.4	208.4	270.1	298.5	56.2	162.4	215.6	239.0
	ESR2013	79.9	221.9	288.8	320.5	53.2	153.5	203.4	224.9



4.1. Lung cancer survival: by region

4.1.1. Lung cancer survival by region, sex and age group: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
		85,705	53.9% (53.6%; 54.3%)	32.7% (32.4%; 33.1%)	25.7% (25.4%; 26.1%)	17.1% (16.4%; 17.8%)
Males						
Belgium	All ages	55,820	51.1% (50.7%; 51.5%)	29.6% (29.1%; 30.0%)	22.6% (22.2%; 23.0%)	14.4% (13.6%; 15.2%)
	15-59	8,630	58.2% (57.1%; 59.2%)	35.1% (34.1%; 36.2%)	28.3% (27.3%; 29.4%)	20.1% (18.9%; 21.5%)
	60-74	28,182	54.9% (54.3%; 55.4%)	32.8% (32.2%; 33.4%)	25.4% (24.8%; 26.0%)	16.2% (15.3%; 17.1%)
	75+	19,112	42.4% (41.7%; 43.2%)	22.3% (21.6%; 23.0%)	15.9% (15.1%; 16.7%)	9.0% (7.4%; 10.9%)
Brussels	All ages	3,836	52.1% (50.5%; 53.8%)	29.3% (27.7%; 31.0%)	22.8% (21.2%; 24.5%)	13.9% (10.9%; 17.7%)
	15-59	887	59.8% (56.6%; 63.1%)	38.4% (35.2%; 41.9%)	31.6% (28.3%; 35.2%)	23.6% (19.5%; 28.7%)
	60-74	1,833	54.2% (51.9%; 56.5%)	29.8% (27.6%; 32.2%)	22.9% (20.8%; 25.3%)	13.7% (10.8%; 17.5%)
	75+	1,126	43.0% (40.0%; 46.2%)	21.6% (18.7%; 24.8%)	15.7% (12.7%; 19.4%)	7.2% (3.0%; 16.9%)
Flanders	All ages	32,883	51.0% (50.5%; 51.6%)	29.7% (29.1%; 30.2%)	23.1% (22.5%; 23.7%)	15.7% (14.6%; 16.9%)
	15-59	4,186	59.7% (58.3%; 61.2%)	36.8% (35.3%; 38.3%)	30.0% (28.5%; 31.5%)	21.9% (19.9%; 24.1%)
	60-74	16,194	55.3% (54.5%; 56.1%)	33.4% (32.6%; 34.2%)	26.2% (25.4%; 27.1%)	17.6% (16.4%; 18.9%)
	75+	12,568	42.7% (41.8%; 43.6%)	22.6% (21.7%; 23.5%)	16.7% (15.8%; 17.7%)	11.0% (8.8%; 13.7%)
Wallonia	All ages	19,105	51.0% (50.3%; 51.8%)	29.4% (28.7%; 30.1%)	21.7% (21.0%; 22.4%)	12.1% (11.1%; 13.2%)

Net Survival Probability, 2013-2022						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	15-59	3,557	56.0% (54.4%; 57.6%)	32.3% (30.8%; 33.9%)	25.5% (24.0%; 27.1%)	17.1% (15.4%; 19.0%)
	60-74	10,158	54.3% (53.3%; 55.3%)	32.5% (31.5%; 33.5%)	24.5% (23.5%; 25.5%)	14.2% (12.9%; 15.6%)
	75+	5,418	41.8% (40.4%; 43.2%)	21.7% (20.4%; 23.0%)	13.9% (12.7%; 15.4%)	5.1% (3.5%; 7.5%)
Females						
Belgium	All ages	29,885	59.2% (58.6%; 59.8%)	38.7% (38.1%; 39.3%)	31.6% (31.0%; 32.3%)	22.3% (21.0%; 23.6%)
	15-59	6,716	67.2% (66.1%; 68.3%)	45.5% (44.3%; 46.7%)	38.3% (37.0%; 39.6%)	30.1% (28.5%; 31.7%)
	60-74	15,477	61.4% (60.6%; 62.2%)	40.4% (39.6%; 41.3%)	32.9% (32.1%; 33.8%)	22.4% (21.2%; 23.8%)
	75+	7,775	48.2% (47.0%; 49.4%)	29.6% (28.4%; 30.8%)	23.3% (22.0%; 24.7%)	14.7% (11.3%; 19.2%)
Brussels	All ages	2,344	58.6% (56.6%; 60.6%)	37.6% (35.5%; 39.8%)	31.0% (28.9%; 33.4%)	25.0% (21.5%; 29.1%)
	15-59	530	64.8% (60.9%; 69.1%)	41.3% (37.2%; 45.9%)	35.1% (30.9%; 39.8%)	26.4% (21.2%; 32.7%)
	60-74	1,124	59.3% (56.4%; 62.3%)	39.1% (36.2%; 42.3%)	32.8% (29.8%; 36.0%)	21.7% (17.3%; 27.1%)
	75+	699	52.8% (49.0%; 56.8%)	32.2% (28.4%; 36.5%)	25.1% (21.0%; 30.1%)	26.8% (18.3%; 39.1%)
Flanders	All ages	16,457	59.6% (58.8%; 60.3%)	38.9% (38.1%; 39.7%)	32.0% (31.1%; 32.9%)	23.0% (21.2%; 25.0%)
	15-59	3,412	66.7% (65.2%; 68.3%)	45.1% (43.4%; 46.9%)	37.7% (35.9%; 39.5%)	30.6% (28.4%; 32.9%)
	60-74	8,519	62.9% (61.8%; 63.9%)	41.4% (40.3%; 42.6%)	34.1% (32.9%; 35.3%)	24.5% (22.7%; 26.4%)
	75+	4,567	48.1% (46.6%; 49.6%)	29.6% (28.1%; 31.2%)	23.9% (22.1%; 25.7%)	14.2% (9.8%; 20.7%)
Wallonia	All ages	11,089	58.9% (57.9%; 59.8%)	38.7% (37.7%; 39.7%)	31.3% (30.3%; 32.3%)	20.5% (18.8%; 22.4%)
	15-59	2,774	68.2% (66.5%; 70.0%)	46.7% (44.9%; 48.7%)	39.6% (37.7%; 41.6%)	30.1% (27.8%; 32.7%)
	60-74	5,837	59.6% (58.4%; 60.9%)	39.2% (37.9%; 40.6%)	31.3% (30.0%; 32.8%)	19.7% (17.8%; 21.7%)
	75+	2,509	47.1% (45.1%; 49.2%)	28.8% (26.8%; 31.0%)	22.0% (19.8%; 24.3%)	10.7% (6.6%; 17.6%)

4.2. Lung cancer survival: by histological type and tumour stage

4.2.2. Lung cancer survival by histological type, clinical stage (cStage) and sex: number at risk and net survival probabilities, 2013-2022

Type	cStage	Net Survival Probability, 2013-2022							
		N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
Total	All	85,705	53.9% (53.6%; 54.3%)	39.6% (39.3%; 40.0%)	32.7% (32.4%; 33.1%)	28.5% (28.2%; 28.9%)	25.7% (25.4%; 26.1%)	17.1% (16.4%; 17.8%)	
Males									
Lung	All	55,820	51.1% (50.7%; 51.5%)	36.4% (36.0%; 36.8%)	29.6% (29.1%; 30.0%)	25.3% (24.8%; 25.7%)	22.6% (22.2%; 23.0%)	14.4% (13.6%; 15.2%)	
	I	10,002	88.6% (87.9%; 89.4%)	77.5% (76.6%; 78.5%)	68.8% (67.6%; 69.9%)	61.6% (60.4%; 62.9%)	56.8% (55.4%; 58.2%)	37.6% (34.4%; 41.1%)	
	II	3,982	75.3% (73.9%; 76.8%)	59.6% (57.9%; 61.3%)	49.9% (48.1%; 51.8%)	43.6% (41.7%; 45.5%)	39.1% (37.1%; 41.2%)	24.6% (21.3%; 28.4%)	
	III	11,308	60.0% (59.1%; 61.0%)	39.9% (39.0%; 40.9%)	30.5% (29.5%; 31.4%)	25.0% (24.1%; 26.0%)	22.1% (21.1%; 23.0%)	14.1% (12.7%; 15.6%)	
	IV	25,664	29.7% (29.1%; 30.2%)	15.4% (15.0%; 15.9%)	10.4% (10.0%; 10.9%)	8.0% (7.6%; 8.4%)	6.5% (6.1%; 6.9%)	3.1% (2.6%; 3.9%)	
	X/NA	5,363	47.6% (46.3%; 49.1%)	36.2% (34.8%; 37.5%)	31.3% (30.0%; 32.7%)	27.3% (26.0%; 28.7%)	24.7% (23.4%; 26.1%)	15.6% (13.6%; 17.9%)	
SCLC	All	7,617	32.8% (31.7%; 33.9%)	14.0% (13.2%; 14.8%)	9.8% (9.1%; 10.5%)	7.6% (7.0%; 8.3%)	6.7% (6.1%; 7.4%)	3.5% (2.7%; 4.5%)	
	I	238	77.6% (72.1%; 83.5%)	49.3% (42.9%; 56.6%)	38.0% (31.7%; 45.5%)	30.7% (24.6%; 38.4%)	30.0% (23.6%; 38.1%)	18.5% (11.1%; 30.7%)	
	II	207	71.0% (64.8%; 77.8%)	44.1% (37.5%; 51.9%)	36.2% (29.8%; 44.0%)	30.1% (23.9%; 38.0%)	28.4% (22.0%; 36.5%)	11.1% (4.5%; 27.6%)	
	III	1,574	55.9% (53.4%; 58.5%)	29.5% (27.2%; 31.9%)	22.1% (20.0%; 24.4%)	17.4% (15.4%; 19.6%)	15.1% (13.1%; 17.3%)	8.2% (5.9%; 11.5%)	
	IV	4,843	23.0% (21.8%; 24.2%)	6.6% (5.9%; 7.4%)	3.5% (3.0%; 4.2%)	2.5% (2.0%; 3.1%)	2.1% (1.6%; 2.7%)	1.3% (0.8%; 2.1%)	
	X/NA	755	23.0% (20.2%; 26.3%)	9.3% (7.4%; 11.7%)	7.3% (5.6%; 9.6%)	5.7% (4.2%; 7.8%)	4.8% (3.4%; 6.9%)	1.2% (0.4%; 3.6%)	
NSCLC	All	42,918	54.6% (54.1%; 55.1%)	40.3% (39.8%; 40.8%)	33.1% (32.6%; 33.6%)	28.5% (28.0%; 29.0%)	25.6% (25.1%; 26.1%)	16.8% (16.0%; 17.7%)	
	I	7,674	90.6% (89.8%; 91.3%)	81.3% (80.3%; 82.4%)	73.3% (72.1%; 74.6%)	66.7% (65.3%; 68.1%)	62.0% (60.5%; 63.6%)	43.0% (39.7%; 46.5%)	
	II	3,338	77.5% (76.0%; 79.1%)	62.9% (61.1%; 64.7%)	53.4% (51.4%; 55.4%)	46.9% (44.9%; 49.1%)	41.8% (39.7%; 44.1%)	26.5% (22.9%; 30.8%)	
	III	8,953	63.0% (62.0%; 64.1%)	43.5% (42.5%; 44.7%)	33.4% (32.4%; 34.5%)	27.7% (26.6%; 28.8%)	24.5% (23.4%; 25.7%)	15.9% (14.4%; 17.6%)	
	IV	19,123	33.0% (32.4%; 33.7%)	18.6% (18.0%; 19.2%)	12.9% (12.4%; 13.4%)	9.8% (9.3%; 10.3%)	8.1% (7.6%; 8.6%)	3.8% (3.0%; 4.8%)	
	X/NA	4,108	51.5% (49.9%; 53.1%)	40.6% (39.0%; 42.2%)	35.1% (33.5%; 36.7%)	30.8% (29.3%; 32.5%)	28.2% (26.7%; 29.9%)	18.7% (16.7%; 21.0%)	

Type	cStage	N at risk	Net Survival Probability, 2013-2022						
			1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
SCC	All	15,589	57.7% (56.8%; 58.5%)	41.4% (40.6%; 42.2%)	33.2% (32.3%; 34.0%)	27.9% (27.1%; 28.8%)	24.6% (23.8%; 25.5%)	15.7% (14.5%; 17.1%)	
	I	2,950	87.5% (86.1%; 88.8%)	75.9% (74.1%; 77.7%)	67.1% (65.0%; 69.2%)	58.3% (56.1%; 60.7%)	52.1% (49.7%; 54.7%)	35.6% (31.2%; 40.8%)	
	II	1,674	76.3% (74.1%; 78.6%)	60.7% (58.2%; 63.4%)	49.3% (46.6%; 52.2%)	43.3% (40.4%; 46.3%)	37.7% (34.7%; 40.9%)	27.1% (22.8%; 32.3%)	
	III	4,656	61.2% (59.7%; 62.7%)	40.8% (39.3%; 42.3%)	30.2% (28.8%; 31.7%)	24.4% (23.0%; 25.9%)	21.6% (20.1%; 23.1%)	13.4% (11.5%; 15.6%)	
	IV	4,824	32.3% (31.0%; 33.7%)	15.7% (14.7%; 16.9%)	10.3% (9.4%; 11.3%)	7.7% (6.8%; 8.6%)	5.9% (5.1%; 6.9%)	3.2% (2.1%; 4.8%)	
	X/NA	1,489	48.8% (46.2%; 51.5%)	36.2% (33.7%; 38.9%)	30.7% (28.3%; 33.4%)	26.4% (24.0%; 29.1%)	23.9% (21.5%; 26.6%)	12.4% (9.8%; 15.7%)	
ADC	All	23,436	54.6% (53.9%; 55.3%)	41.3% (40.6%; 41.9%)	34.2% (33.5%; 34.9%)	29.7% (29.0%; 30.4%)	26.9% (26.2%; 27.6%)	17.1% (15.9%; 18.4%)	
	I	4,127	93.1% (92.2%; 94.1%)	85.6% (84.3%; 86.9%)	78.0% (76.4%; 79.6%)	72.5% (70.6%; 74.3%)	68.4% (66.3%; 70.5%)	46.5% (41.6%; 52.1%)	
	II	1,409	80.6% (78.4%; 82.9%)	66.8% (64.2%; 69.6%)	59.8% (56.9%; 62.9%)	52.6% (49.5%; 55.9%)	47.7% (44.4%; 51.3%)	22.4% (16.2%; 31.1%)	
	III	3,545	67.2% (65.6%; 68.8%)	48.5% (46.7%; 50.3%)	38.2% (36.5%; 40.0%)	32.0% (30.2%; 33.8%)	28.4% (26.6%; 30.3%)	17.5% (14.9%; 20.5%)	
	IV	12,299	34.9% (34.0%; 35.8%)	20.7% (19.9%; 21.4%)	14.4% (13.8%; 15.1%)	11.1% (10.5%; 11.8%)	9.2% (8.6%; 9.9%)	4.2% (3.2%; 5.5%)	
	X/NA	2,118	56.5% (54.3%; 58.7%)	46.2% (44.0%; 48.6%)	40.4% (38.2%; 42.8%)	35.6% (33.4%; 38.0%)	32.7% (30.4%; 35.1%)	23.0% (20.0%; 26.5%)	
LCC	All	1,129	33.9% (31.2%; 36.8%)	22.5% (20.1%; 25.3%)	17.8% (15.5%; 20.5%)	14.7% (12.4%; 17.4%)	13.1% (10.7%; 16.0%)	7.1% (4.4%; 11.7%)	
	I	86	81.6% (72.9%; 91.3%)	64.0% (53.5%; 76.7%)	53.8% (42.8%; 67.7%)	49.6% (37.7%; 65.3%)	42.6% (30.5%; 59.4%)	24.7% (11.9%; 51.5%)	
	II	60	69.4% (58.2%; 82.8%)	62.2% (50.1%; 77.2%)	48.6% (35.7%; 66.3%)	44.7% (31.1%; 64.2%)	35.2% (20.8%; 59.6%)	21.2% (6.8%; 65.7%)	
	III	204	52.1% (45.5%; 59.7%)	37.1% (30.7%; 44.8%)	30.9% (24.6%; 38.8%)	25.1% (18.9%; 33.2%)	24.6% (18.3%; 33.0%)	18.4% (10.9%; 31.1%)	
	IV	635	21.0% (18.0%; 24.5%)	10.2% (7.9%; 13.0%)	7.3% (5.3%; 10.1%)	4.0% (2.4%; 6.6%)	3.6% (2.1%; 6.3%)	FU<10y	
	X/NA	144	21.3% (15.5%; 29.4%)	14.3% (9.4%; 21.8%)	10.7% (6.4%; 17.8%)	10.1% (5.9%; 17.3%)	9.6% (5.4%; 16.9%)	FU<10y	
Other NSCLC	All	3,091	48.2% (46.4%; 50.0%)	36.5% (34.7%; 38.3%)	31.6% (29.8%; 33.4%)	28.7% (26.9%; 30.6%)	27.1% (25.3%; 29.1%)	22.9% (20.2%; 26.0%)	
	I	567	89.8% (86.9%; 92.6%)	81.3% (77.6%; 85.2%)	75.3% (70.9%; 79.9%)	71.3% (66.5%; 76.5%)	70.8% (65.7%; 76.4%)	60.9% (51.3%; 72.3%)	
	II	209	70.0% (63.7%; 76.9%)	55.9% (48.9%; 63.8%)	46.7% (39.4%; 55.4%)	40.8% (33.4%; 49.9%)	40.9% (32.9%; 50.9%)	32.3% (19.3%; 54.1%)	
	III	564	56.1% (52.0%; 60.6%)	37.9% (33.8%; 42.4%)	31.4% (27.5%; 36.0%)	29.0% (24.9%; 33.6%)	25.1% (20.9%; 30.2%)	23.9% (18.4%; 31.0%)	
	IV	1,374	24.6% (22.4%; 27.0%)	14.0% (12.2%; 16.0%)	10.6% (9.0%; 12.5%)	8.2% (6.7%; 10.1%)	7.2% (5.7%; 9.1%)	4.0% (2.3%; 6.9%)	
	X/NA	378	48.0% (43.1%; 53.5%)	38.7% (33.8%; 44.2%)	34.2% (29.3%; 39.8%)	31.8% (27.0%; 37.6%)	29.4% (24.6%; 35.3%)	26.3% (20.2%; 34.3%)	

Net Survival Probability, 2013-2022									
Type	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
Other	All	5,591	49.5% (48.1%; 51.0%)	36.9% (35.5%; 38.4%)	29.5% (28.1%; 31.0%)	24.7% (23.2%; 26.3%)	20.9% (19.4%; 22.6%)	10.1% (6.8%; 15.0%)	
	I	2,139	82.8% (81.0%; 84.7%)	66.9% (64.6%; 69.4%)	55.4% (52.7%; 58.2%)	46.3% (43.3%; 49.5%)	39.7% (36.4%; 43.3%)	18.7% (11.8%; 29.6%)	
	II	442	60.9% (56.0%; 66.1%)	42.1% (37.0%; 47.8%)	30.1% (25.1%; 36.1%)	24.5% (19.4%; 30.8%)	23.3% (17.9%; 30.2%)	13.5% (6.8%; 27.0%)	
	III	795	34.7% (31.3%; 38.4%)	19.8% (16.9%; 23.2%)	13.4% (10.8%; 16.6%)	10.6% (8.0%; 13.9%)	8.0% (5.7%; 11.4%)	6.5% (2.8%; 14.8%)	
	IV	1,711	10.9% (9.5%; 12.6%)	5.2% (4.1%; 6.5%)	2.7% (1.9%; 3.9%)	2.4% (1.7%; 3.6%)	1.6% (0.9%; 2.8%)	0.8% (0.2%; 2.6%)	
	X/NA	508	53.0% (48.6%; 57.9%)	40.0% (35.5%; 45.1%)	36.4% (31.6%; 41.9%)	31.3% (26.4%; 37.1%)	25.8% (20.9%; 31.9%)	10.3% (3.5%; 30.0%)	
Females									
Lung	All	29,885	59.2% (58.6%; 59.8%)	45.6% (45.0%; 46.2%)	38.7% (38.1%; 39.3%)	34.7% (34.0%; 35.3%)	31.6% (31.0%; 32.3%)	22.3% (21.0%; 23.6%)	
	I	6,431	92.7% (92.0%; 93.5%)	85.3% (84.3%; 86.3%)	79.0% (77.8%; 80.2%)	74.3% (72.9%; 75.7%)	69.8% (68.3%; 71.4%)	51.2% (47.8%; 54.8%)	
	II	1,781	80.4% (78.5%; 82.4%)	67.1% (64.8%; 69.5%)	59.7% (57.2%; 62.3%)	53.3% (50.6%; 56.2%)	48.4% (45.5%; 51.5%)	29.1% (21.8%; 38.9%)	
	III	5,243	65.3% (63.9%; 66.6%)	46.5% (45.2%; 48.0%)	37.5% (36.1%; 38.9%)	32.4% (31.0%; 33.9%)	28.9% (27.4%; 30.4%)	18.7% (16.8%; 20.9%)	
	IV	13,889	39.0% (38.2%; 39.8%)	23.5% (22.8%; 24.3%)	16.8% (16.2%; 17.5%)	13.4% (12.8%; 14.1%)	11.3% (10.7%; 12.0%)	5.7% (4.1%; 7.9%)	
	X/NA	2,837	58.9% (57.1%; 60.8%)	49.6% (47.7%; 51.5%)	44.5% (42.6%; 46.5%)	41.7% (39.7%; 43.8%)	39.0% (37.0%; 41.1%)	32.1% (29.1%; 35.3%)	
SCLC	All	4,511	41.9% (40.5%; 43.4%)	22.0% (20.8%; 23.3%)	15.4% (14.3%; 16.5%)	12.2% (11.2%; 13.3%)	10.7% (9.7%; 11.8%)	6.4% (5.2%; 7.8%)	
	I	171	84.4% (78.8%; 90.3%)	61.9% (54.6%; 70.0%)	49.8% (42.3%; 58.7%)	40.3% (32.7%; 49.7%)	37.6% (29.9%; 47.4%)	30.8% (21.5%; 44.1%)	
	II	137	74.8% (67.7%; 82.7%)	54.1% (46.0%; 63.5%)	46.5% (38.2%; 56.5%)	38.3% (29.7%; 49.3%)	33.1% (24.5%; 44.6%)	12.3% (4.4%; 34.3%)	
	III	1,078	63.5% (60.6%; 66.5%)	38.4% (35.5%; 41.5%)	28.2% (25.5%; 31.2%)	22.4% (19.8%; 25.4%)	20.5% (17.9%; 23.4%)	11.9% (8.9%; 16.0%)	
	IV	2,721	30.0% (28.4%; 31.8%)	11.7% (10.5%; 13.0%)	6.8% (5.8%; 7.9%)	4.9% (4.1%; 6.0%)	3.9% (3.1%; 4.9%)	2.7% (2.0%; 3.8%)	
	X/NA	404	35.3% (30.9%; 40.3%)	19.6% (16.1%; 24.0%)	14.0% (10.9%; 18.0%)	12.5% (9.5%; 16.5%)	10.6% (7.8%; 14.4%)	5.0% (2.7%; 9.5%)	
NSCLC	All	22,719	62.9% (62.3%; 63.6%)	50.1% (49.4%; 50.8%)	43.2% (42.5%; 43.9%)	39.0% (38.3%; 39.7%)	35.7% (34.9%; 36.4%)	25.9% (24.7%; 27.3%)	
	I	5,022	94.9% (94.2%; 95.6%)	89.0% (88.0%; 90.0%)	83.7% (82.5%; 85.0%)	79.9% (78.5%; 81.3%)	75.4% (73.8%; 77.1%)	56.7% (52.8%; 60.8%)	
	II	1,449	83.6% (81.6%; 85.6%)	71.2% (68.7%; 73.8%)	64.1% (61.4%; 66.9%)	57.9% (55.0%; 61.0%)	52.4% (49.2%; 55.8%)	31.5% (23.2%; 42.8%)	
	III	3,841	68.2% (66.7%; 69.7%)	50.9% (49.2%; 52.6%)	42.0% (40.3%; 43.7%)	36.8% (35.1%; 38.5%)	32.9% (31.2%; 34.7%)	21.8% (19.4%; 24.5%)	
	IV	10,430	43.0% (42.0%; 44.0%)	27.6% (26.7%; 28.5%)	20.1% (19.2%; 20.9%)	16.0% (15.2%; 16.8%)	13.4% (12.6%; 14.2%)	7.1% (6.0%; 8.3%)	

Type	cStage	N at risk	Net Survival Probability, 2013-2022						
			1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
	X/NA	2,133	62.9% (60.9%; 65.1%)	54.9% (52.7%; 57.1%)	49.7% (47.5%; 52.0%)	46.8% (44.6%; 49.2%)	44.1% (41.7%; 46.5%)	38.0% (34.9%; 41.5%)	
SCC	All	4,223	60.3% (58.8%; 61.8%)	44.8% (43.3%; 46.4%)	37.1% (35.5%; 38.7%)	33.2% (31.7%; 34.9%)	29.5% (27.9%; 31.2%)	18.5% (16.3%; 21.1%)	
	I	909	90.9% (88.9%; 93.0%)	79.9% (77.1%; 82.9%)	71.4% (68.1%; 74.8%)	65.8% (62.2%; 69.7%)	58.1% (54.0%; 62.4%)	33.2% (26.4%; 41.7%)	
	II	412	76.7% (72.5%; 81.1%)	60.6% (55.8%; 65.9%)	51.4% (46.3%; 57.1%)	44.6% (39.4%; 50.7%)	39.3% (33.9%; 45.7%)	26.2% (17.8%; 38.7%)	
	III	1,190	59.0% (56.3%; 62.0%)	39.0% (36.2%; 42.0%)	30.2% (27.6%; 33.2%)	27.3% (24.6%; 30.2%)	23.9% (21.2%; 26.9%)	15.1% (11.8%; 19.4%)	
	IV	1,320	34.9% (32.4%; 37.6%)	19.1% (17.1%; 21.4%)	12.9% (11.1%; 15.0%)	10.2% (8.5%; 12.2%)	8.9% (7.2%; 11.0%)	5.3% (3.2%; 8.7%)	
	X/NA	393	61.1% (56.4%; 66.3%)	51.3% (46.4%; 56.7%)	44.3% (39.3%; 49.9%)	40.9% (35.9%; 46.6%)	38.1% (33.1%; 43.9%)	26.5% (20.4%; 34.3%)	
ADC	All	16,126	64.0% (63.2%; 64.7%)	51.3% (50.5%; 52.1%)	44.0% (43.2%; 44.9%)	39.4% (38.6%; 40.3%)	35.8% (34.9%; 36.7%)	25.6% (24.1%; 27.3%)	
	I	3,428	95.7% (94.9%; 96.5%)	90.4% (89.3%; 91.6%)	85.3% (83.8%; 86.7%)	81.4% (79.7%; 83.2%)	77.0% (75.0%; 79.0%)	57.6% (52.9%; 62.8%)	
	II	877	86.2% (83.8%; 88.7%)	75.3% (72.3%; 78.5%)	68.7% (65.3%; 72.2%)	62.4% (58.6%; 66.3%)	55.6% (51.5%; 60.1%)	31.6% (20.9%; 47.8%)	
	III	2,295	73.8% (72.0%; 75.7%)	58.0% (55.9%; 60.1%)	48.8% (46.6%; 51.1%)	41.9% (39.7%; 44.3%)	37.4% (35.1%; 39.9%)	26.0% (22.6%; 29.8%)	
	IV	8,160	45.8% (44.7%; 46.9%)	30.0% (29.0%; 31.1%)	21.8% (20.9%; 22.8%)	17.3% (16.4%; 18.3%)	14.3% (13.4%; 15.3%)	7.3% (6.1%; 8.7%)	
	X/NA	1,439	63.7% (61.2%; 66.3%)	55.0% (52.4%; 57.7%)	49.9% (47.2%; 52.8%)	47.2% (44.5%; 50.1%)	44.0% (41.2%; 47.0%)	37.1% (33.1%; 41.5%)	
LCC	All	488	39.0% (34.9%; 43.6%)	27.9% (24.1%; 32.4%)	23.4% (19.8%; 27.8%)	21.8% (18.2%; 26.3%)	21.6% (17.9%; 26.2%)	14.7% (9.1%; 23.7%)	
	I	48	N<50	N<50	N<50	N<50	N<50	N<50	
	II	29	N<50	N<50	N<50	N<50	N<50	N<50	
	III	85	59.9% (50.2%; 71.6%)	40.8% (31.2%; 53.5%)	34.1% (24.9%; 46.8%)	32.2% (22.9%; 45.3%)	32.6% (23.1%; 45.9%)	FU<10y	
	IV	274	22.3% (17.8%; 27.8%)	12.0% (8.7%; 16.7%)	8.6% (5.7%; 13.1%)	8.7% (5.8%; 13.2%)	8.8% (5.8%; 13.3%)	FU<10y	
	X/NA	52	29.2% (19.2%; 44.4%)	27.7% (17.9%; 42.9%)	21.9% (13.1%; 36.7%)	22.2% (13.3%; 37.2%)	20.1% (11.5%; 35.1%)	16.6% (8.7%; 31.8%)	
Other NSCLC	All	2,037	67.2% (65.2%; 69.4%)	58.6% (56.4%; 60.8%)	55.2% (52.9%; 57.6%)	52.8% (50.4%; 55.3%)	51.9% (49.4%; 54.6%)	46.8% (42.7%; 51.3%)	
	I	682	97.3% (95.8%; 98.8%)	94.6% (92.5%; 96.8%)	93.1% (90.5%; 95.8%)	91.4% (88.3%; 94.7%)	90.7% (87.1%; 94.4%)	82.9% (72.5%; 94.8%)	
	II	141	88.0% (82.4%; 93.9%)	76.6% (69.4%; 84.6%)	72.8% (64.9%; 81.7%)	70.4% (61.9%; 80.1%)	71.7% (62.7%; 82.0%)	61.6% (46.6%; 81.4%)	
	III	273	63.0% (57.4%; 69.1%)	45.9% (40.1%; 52.5%)	38.9% (33.1%; 45.7%)	37.1% (31.2%; 44.2%)	35.7% (29.5%; 43.3%)	18.9% (11.5%; 31.0%)	
	IV	681	33.6% (30.2%; 37.4%)	20.9% (18.0%; 24.3%)	17.2% (14.5%; 20.5%)	14.7% (12.0%; 17.9%)	13.3% (10.6%; 16.5%)	8.1% (5.0%; 13.1%)	

Net Survival Probability, 2013-2022									
Type	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
	X/NA	261	69.8% (64.3%; 75.8%)	66.3% (60.5%; 72.6%)	63.3% (57.3%; 69.9%)	59.4% (53.2%; 66.4%)	59.2% (52.8%; 66.4%)	64.6% (56.9%; 73.4%)	
Other	All	2,840	57.1% (55.2%; 59.0%)	46.6% (44.6%; 48.7%)	40.0% (38.0%; 42.2%)	35.4% (33.2%; 37.7%)	32.4% (30.1%; 34.9%)	16.5% (10.1%; 26.9%)	
	I	1,264	85.1% (82.9%; 87.3%)	73.2% (70.4%; 76.1%)	63.4% (60.2%; 66.8%)	55.3% (51.7%; 59.2%)	50.4% (46.4%; 54.6%)	29.7% (22.7%; 38.9%)	
	II	197	60.9% (54.0%; 68.6%)	45.5% (38.3%; 54.1%)	36.3% (28.9%; 45.5%)	28.9% (21.2%; 39.3%)	29.7% (21.4%; 41.3%)	26.2% (13.8%; 50.0%)	
	III	330	36.9% (31.9%; 42.8%)	22.4% (18.0%; 27.9%)	15.5% (11.6%; 20.8%)	14.4% (10.5%; 19.9%)	9.6% (6.2%; 14.9%)	6.1% (2.5%; 15.4%)	
	IV	748	15.5% (13.0%; 18.4%)	10.1% (8.0%; 12.8%)	8.9% (6.8%; 11.7%)	8.9% (6.6%; 12.0%)	9.8% (7.2%; 13.2%)	1.7% (0.3%; 10.8%)	
	X/NA	303	62.0% (56.5%; 68.1%)	52.5% (46.7%; 59.1%)	49.1% (43.0%; 56.2%)	45.0% (38.4%; 52.8%)	42.0% (35.0%; 50.5%)	17.3% (7.3%; 40.8%)	

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

4.2.3. Lung cancer survival by histological type, pathological stage (pStage) and sex: number at risk and net survival probabilities, 2013-2022

Type	Net Survival Probability, 2013-2022								
	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
Total	All	85,705	53.9% (53.6%; 54.3%)	39.6% (39.3%; 40.0%)	32.7% (32.4%; 33.1%)	28.5% (28.2%; 28.9%)	25.7% (25.4%; 26.1%)	17.1% (16.4%; 17.8%)	
Males									
Lung	All	55,820	51.1% (50.7%; 51.5%)	36.4% (36.0%; 36.8%)	29.6% (29.1%; 30.0%)	25.3% (24.8%; 25.7%)	22.6% (22.2%; 23.0%)	14.4% (13.6%; 15.2%)	
	I	5,898	95.0% (94.3%; 95.7%)	89.8% (88.9%; 90.8%)	85.1% (84.0%; 86.3%)	80.8% (79.5%; 82.2%)	77.4% (75.8%; 79.0%)	58.4% (55.0%; 62.0%)	
	II	2,569	88.8% (87.4%; 90.2%)	77.5% (75.7%; 79.4%)	70.8% (68.8%; 72.9%)	63.8% (61.5%; 66.1%)	59.1% (56.6%; 61.6%)	45.4% (41.0%; 50.2%)	
	III	1,809	74.3% (72.2%; 76.4%)	56.9% (54.5%; 59.3%)	46.9% (44.4%; 49.5%)	40.8% (38.3%; 43.6%)	36.5% (33.9%; 39.3%)	24.4% (19.8%; 30.1%)	
	IV	3,597	30.2% (28.8%; 31.8%)	17.8% (16.5%; 19.1%)	13.3% (12.2%; 14.6%)	10.5% (9.5%; 11.8%)	8.9% (7.9%; 10.1%)	5.6% (4.2%; 7.4%)	
	X/NA	42,317	43.6% (43.1%; 44.1%)	27.3% (26.9%; 27.8%)	20.0% (19.6%; 20.5%)	15.8% (15.3%; 16.2%)	13.2% (12.8%; 13.7%)	6.1% (5.3%; 7.0%)	
SCLC	All	7,617	32.8% (31.7%; 33.9%)	14.0% (13.2%; 14.8%)	9.8% (9.1%; 10.5%)	7.6% (7.0%; 8.3%)	6.7% (6.1%; 7.4%)	3.5% (2.7%; 4.5%)	
	I	97	85.5% (78.2%; 93.4%)	59.5% (49.8%; 71.0%)	51.8% (41.7%; 64.2%)	42.4% (32.3%; 55.7%)	42.0% (31.7%; 55.8%)	22.9% (10.9%; 48.0%)	
	II	67	74.9% (64.8%; 86.6%)	51.7% (40.6%; 65.8%)	46.7% (35.5%; 61.3%)	43.2% (32.0%; 58.2%)	42.7% (31.3%; 58.3%)	20.0% (8.9%; 44.6%)	
	III	102	39.2% (30.7%; 50.0%)	21.3% (14.6%; 31.2%)	14.3% (8.8%; 23.3%)	11.2% (6.3%; 19.9%)	9.0% (4.7%; 17.4%)	FU<10y	
	IV	609	19.6% (16.6%; 23.0%)	6.1% (4.4%; 8.4%)	2.9% (1.8%; 4.8%)	2.2% (1.2%; 4.0%)	1.6% (0.8%; 3.4%)	0.7% (0.2%; 2.5%)	
	X/NA	6,742	32.7% (31.6%; 33.9%)	13.6% (12.7%; 14.4%)	9.4% (8.6%; 10.1%)	7.2% (6.5%; 7.9%)	6.2% (5.6%; 7.0%)	3.4% (2.6%; 4.4%)	
NSCLC	All	42,918	54.6% (54.1%; 55.1%)	40.3% (39.8%; 40.8%)	33.1% (32.6%; 33.6%)	28.5% (28.0%; 29.0%)	25.6% (25.1%; 26.1%)	16.8% (16.0%; 17.7%)	
	I	5,807	95.2% (94.5%; 95.9%)	90.3% (89.4%; 91.3%)	85.7% (84.5%; 86.9%)	81.5% (80.1%; 82.9%)	77.9% (76.4%; 79.6%)	59.0% (55.6%; 62.7%)	
	II	2,504	89.1% (87.7%; 90.5%)	78.1% (76.3%; 80.0%)	71.3% (69.3%; 73.5%)	64.2% (61.9%; 66.6%)	59.4% (56.9%; 62.0%)	46.1% (41.7%; 51.0%)	
	III	1,706	76.4% (74.3%; 78.5%)	59.0% (56.6%; 61.6%)	48.9% (46.4%; 51.7%)	42.7% (40.0%; 45.5%)	38.2% (35.5%; 41.2%)	26.1% (21.2%; 32.1%)	
	IV	2,983	32.5% (30.8%; 34.3%)	20.2% (18.8%; 21.8%)	15.5% (14.2%; 17.0%)	12.3% (11.0%; 13.7%)	10.5% (9.2%; 11.9%)	6.5% (4.8%; 8.7%)	
	X/NA	30,147	45.0% (44.4%; 45.6%)	28.7% (28.1%; 29.2%)	20.7% (20.2%; 21.2%)	16.1% (15.6%; 16.6%)	13.4% (12.9%; 13.9%)	6.0% (5.3%; 6.9%)	
SCC	All	15,589	57.7% (56.8%; 58.5%)	41.4% (40.6%; 42.2%)	33.2% (32.3%; 34.0%)	27.9% (27.1%; 28.8%)	24.6% (23.8%; 25.5%)	15.7% (14.5%; 17.1%)	
	I	1,935	93.3% (91.9%; 94.6%)	86.9% (85.0%; 88.7%)	81.4% (79.2%; 83.6%)	75.9% (73.4%; 78.5%)	70.4% (67.5%; 73.3%)	49.8% (44.4%; 55.8%)	

Net Survival Probability, 2013-2022									
Type	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
	II	1,086	89.6% (87.6%; 91.7%)	78.6% (75.9%; 81.4%)	72.6% (69.5%; 75.8%)	66.2% (62.7%; 69.8%)	60.0% (56.3%; 64.1%)	51.6% (45.2%; 58.9%)	
	III	639	77.2% (73.8%; 80.7%)	58.5% (54.5%; 62.8%)	48.0% (43.8%; 52.5%)	40.9% (36.6%; 45.6%)	37.4% (33.0%; 42.3%)	26.5% (20.7%; 34.0%)	
	IV	484	30.7% (26.7%; 35.2%)	16.4% (13.3%; 20.2%)	12.3% (9.6%; 15.9%)	10.5% (7.9%; 14.1%)	7.7% (5.4%; 11.1%)	FU<10y	
	X/NA	11,449	48.7% (47.7%; 49.6%)	30.3% (29.4%; 31.2%)	21.2% (20.4%; 22.1%)	16.0% (15.2%; 16.8%)	13.2% (12.4%; 14.0%)	5.9% (4.9%; 7.1%)	
ADC	All	23,436	54.6% (53.9%; 55.3%)	41.3% (40.6%; 41.9%)	34.2% (33.5%; 34.9%)	29.7% (29.0%; 30.4%)	26.9% (26.2%; 27.6%)	17.1% (15.9%; 18.4%)	
	I	3,424	96.4% (95.6%; 97.2%)	92.6% (91.5%; 93.8%)	88.1% (86.7%; 89.6%)	84.3% (82.6%; 86.1%)	81.4% (79.4%; 83.4%)	61.6% (57.0%; 66.7%)	
	II	1,245	89.6% (87.7%; 91.5%)	78.2% (75.6%; 80.8%)	70.6% (67.7%; 73.6%)	62.7% (59.5%; 66.1%)	58.2% (54.8%; 61.9%)	37.5% (31.2%; 45.1%)	
	III	917	77.0% (74.2%; 79.9%)	59.8% (56.5%; 63.2%)	49.2% (45.7%; 52.9%)	43.3% (39.8%; 47.2%)	38.2% (34.6%; 42.2%)	24.8% (17.9%; 34.3%)	
	IV	2,117	34.0% (32.0%; 36.1%)	21.6% (19.8%; 23.5%)	16.6% (14.9%; 18.4%)	13.2% (11.6%; 14.9%)	11.4% (9.9%; 13.2%)	7.5% (5.6%; 10.1%)	
	X/NA	15,805	44.4% (43.6%; 45.2%)	28.9% (28.2%; 29.7%)	21.2% (20.5%; 21.9%)	16.7% (16.0%; 17.4%)	13.9% (13.3%; 14.7%)	6.0% (4.8%; 7.4%)	
LCC	All	1,129	33.9% (31.2%; 36.8%)	22.5% (20.1%; 25.3%)	17.8% (15.5%; 20.5%)	14.7% (12.4%; 17.4%)	13.1% (10.7%; 16.0%)	7.1% (4.4%; 11.7%)	
	I	46	N<50	N<50	N<50	N<50	N<50	N<50	
	II	39	N<50	N<50	N<50	N<50	N<50	N<50	
	III	37	N<50	N<50	N<50	N<50	N<50	N<50	
	IV	112	25.0% (18.1%; 34.5%)	14.1% (8.6%; 23.0%)	10.6% (5.9%; 19.3%)	7.2% (3.3%; 16.0%)	7.3% (3.3%; 16.0%)	FU<10y	
	X/NA	895	28.9% (26.0%; 32.2%)	17.8% (15.3%; 20.6%)	13.3% (11.0%; 16.1%)	10.1% (7.9%; 12.9%)	8.2% (6.0%; 11.1%)	2.3% (0.9%; 6.3%)	
Other NSCLC	All	3,091	48.2% (46.4%; 50.0%)	36.5% (34.7%; 38.3%)	31.6% (29.8%; 33.4%)	28.7% (26.9%; 30.6%)	27.1% (25.3%; 29.1%)	22.9% (20.2%; 26.0%)	
	I	463	95.1% (92.8%; 97.5%)	89.8% (86.5%; 93.2%)	87.5% (83.7%; 91.5%)	85.4% (81.0%; 90.1%)	85.0% (80.2%; 90.2%)	79.4% (70.1%; 89.9%)	
	II	139	81.2% (74.6%; 88.4%)	73.8% (66.1%; 82.3%)	67.5% (59.1%; 77.2%)	60.3% (51.1%; 71.2%)	62.3% (52.8%; 73.6%)	57.5% (41.6%; 79.3%)	
	III	113	74.9% (67.0%; 83.8%)	63.6% (54.6%; 74.0%)	58.4% (49.0%; 69.6%)	53.2% (43.4%; 65.3%)	46.9% (36.6%; 60.0%)	45.7% (33.3%; 62.7%)	
	IV	270	27.4% (22.5%; 33.4%)	18.9% (14.6%; 24.5%)	15.0% (11.0%; 20.4%)	10.6% (7.1%; 15.9%)	9.7% (6.3%; 15.1%)	6.4% (3.1%; 13.0%)	
	X/NA	2,108	37.1% (35.0%; 39.2%)	23.2% (21.4%; 25.2%)	17.7% (15.9%; 19.6%)	15.2% (13.5%; 17.1%)	13.3% (11.5%; 15.3%)	8.1% (5.5%; 11.8%)	
Other	All	5,591	49.5% (48.1%; 51.0%)	36.9% (35.5%; 38.4%)	29.5% (28.1%; 31.0%)	24.7% (23.2%; 26.3%)	20.9% (19.4%; 22.6%)	10.1% (6.8%; 15.0%)	
	I	0	N<50	N<50	N<50	N<50	N<50	N<50	

Net Survival Probability, 2013-2022									
Type	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
	II	1	N<50	N<50	N<50	N<50	N<50	N<50	
	III	1	N<50	N<50	N<50	N<50	N<50	N<50	
	IV	7	N<50	N<50	N<50	N<50	N<50	N<50	
	X/NA	5,582	49.6% (48.2%; 51.0%)	37.0% (35.6%; 38.4%)	29.6% (28.1%; 31.1%)	24.7% (23.2%; 26.3%)	20.9% (19.4%; 22.6%)	10.1% (6.8%; 15.0%)	
Females									
Lung	All	29,885	59.2% (58.6%; 59.8%)	45.6% (45.0%; 46.2%)	38.7% (38.1%; 39.3%)	34.7% (34.0%; 35.3%)	31.6% (31.0%; 32.3%)	22.3% (21.0%; 23.6%)	
	I	4,178	98.3% (97.8%; 98.8%)	95.8% (95.0%; 96.6%)	92.4% (91.4%; 93.5%)	89.7% (88.4%; 91.0%)	86.5% (85.0%; 88.0%)	75.0% (71.4%; 78.7%)	
	II	1,269	91.1% (89.5%; 92.8%)	83.9% (81.7%; 86.1%)	79.6% (77.1%; 82.2%)	73.8% (70.9%; 76.7%)	68.6% (65.4%; 72.0%)	50.3% (44.2%; 57.3%)	
	III	958	84.2% (81.9%; 86.7%)	71.5% (68.6%; 74.6%)	62.2% (59.0%; 65.7%)	55.5% (52.0%; 59.2%)	49.9% (46.3%; 53.8%)	37.4% (32.4%; 43.2%)	
	IV	2,017	41.0% (38.9%; 43.2%)	26.7% (24.8%; 28.8%)	19.6% (17.9%; 21.6%)	16.1% (14.4%; 18.0%)	13.5% (11.9%; 15.4%)	7.9% (6.1%; 10.3%)	
	X/NA	21,684	50.6% (49.9%; 51.3%)	34.4% (33.8%; 35.1%)	26.8% (26.2%; 27.5%)	22.6% (22.0%; 23.2%)	19.7% (19.0%; 20.4%)	10.7% (9.3%; 12.2%)	
SCLC	All	4,511	41.9% (40.5%; 43.4%)	22.0% (20.8%; 23.3%)	15.4% (14.3%; 16.5%)	12.2% (11.2%; 13.3%)	10.7% (9.7%; 11.8%)	6.4% (5.2%; 7.8%)	
	I	75	94.3% (88.8%; 100.1%)	80.1% (71.1%; 90.2%)	68.9% (58.6%; 81.1%)	60.5% (49.3%; 74.2%)	56.8% (45.2%; 71.4%)	47.9% (33.4%; 68.8%)	
	II	33	N<50	N<50	N<50	N<50	N<50	N<50	
	III	35	N<50	N<50	N<50	N<50	N<50	N<50	
	IV	329	30.0% (25.4%; 35.4%)	11.8% (8.8%; 16.0%)	7.0% (4.7%; 10.6%)	5.1% (3.1%; 8.5%)	4.1% (2.2%; 7.4%)	FU<10y	
	X/NA	4,039	41.3% (39.8%; 42.9%)	21.1% (19.8%; 22.4%)	14.6% (13.5%; 15.8%)	11.5% (10.5%; 12.7%)	10.0% (9.0%; 11.2%)	5.6% (4.4%; 7.0%)	
NSCLC	All	22,719	62.9% (62.3%; 63.6%)	50.1% (49.4%; 50.8%)	43.2% (42.5%; 43.9%)	39.0% (38.3%; 39.7%)	35.7% (34.9%; 36.4%)	25.9% (24.7%; 27.3%)	
	I	4,107	98.4% (97.9%; 98.9%)	96.1% (95.3%; 96.9%)	92.9% (91.8%; 93.9%)	90.2% (88.9%; 91.5%)	87.1% (85.5%; 88.6%)	75.5% (71.8%; 79.3%)	
	II	1,236	91.3% (89.6%; 93.0%)	84.2% (82.0%; 86.5%)	80.1% (77.7%; 82.7%)	74.4% (71.5%; 77.4%)	69.3% (66.0%; 72.7%)	50.7% (44.6%; 57.8%)	
	III	923	84.7% (82.3%; 87.1%)	72.3% (69.4%; 75.4%)	63.4% (60.1%; 66.8%)	57.0% (53.5%; 60.7%)	51.2% (47.4%; 55.2%)	38.2% (33.0%; 44.2%)	
	IV	1,682	43.3% (40.9%; 45.7%)	29.7% (27.6%; 32.1%)	22.2% (20.2%; 24.4%)	18.4% (16.4%; 20.6%)	15.5% (13.6%; 17.7%)	9.0% (6.8%; 11.8%)	
	X/NA	14,901	51.9% (51.0%; 52.7%)	35.7% (35.0%; 36.6%)	27.6% (26.9%; 28.4%)	23.2% (22.4%; 24.0%)	20.0% (19.2%; 20.8%)	10.9% (9.6%; 12.4%)	
SCC	All	4,223	60.3% (58.8%; 61.8%)	44.8% (43.3%; 46.4%)	37.1% (35.5%; 38.7%)	33.2% (31.7%; 34.9%)	29.5% (27.9%; 31.2%)	18.5% (16.3%; 21.1%)	

Net Survival Probability, 2013-2022									
Type	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
	I	618	96.7% (95.1%; 98.4%)	92.3% (89.8%; 94.9%)	86.9% (83.7%; 90.3%)	81.7% (77.9%; 85.7%)	76.1% (71.7%; 80.8%)	53.4% (45.3%; 62.9%)	
	II	260	88.1% (84.1%; 92.4%)	79.2% (74.1%; 84.7%)	75.7% (70.0%; 81.8%)	69.7% (63.4%; 76.6%)	62.0% (54.9%; 70.0%)	49.5% (37.4%; 65.6%)	
	III	155	78.5% (72.1%; 85.5%)	59.8% (52.2%; 68.4%)	48.9% (41.2%; 58.1%)	44.6% (36.7%; 54.1%)	43.6% (35.6%; 53.5%)	34.7% (24.2%; 49.8%)	
	IV	125	37.4% (29.7%; 46.9%)	18.1% (12.3%; 26.5%)	14.6% (9.4%; 22.6%)	13.8% (8.7%; 21.9%)	10.9% (6.2%; 19.2%)	FU<10y	
	X/NA	3,066	50.6% (48.8%; 52.4%)	32.7% (31.0%; 34.4%)	24.0% (22.4%; 25.7%)	20.5% (18.9%; 22.1%)	17.2% (15.6%; 18.9%)	7.9% (6.0%; 10.4%)	
ADC	AII	16,126	64.0% (63.2%; 64.7%)	51.3% (50.5%; 52.1%)	44.0% (43.2%; 44.9%)	39.4% (38.6%; 40.3%)	35.8% (34.9%; 36.7%)	25.6% (24.1%; 27.3%)	
	I	2,895	98.6% (98.0%; 99.2%)	96.2% (95.3%; 97.1%)	92.9% (91.7%; 94.2%)	90.6% (89.1%; 92.1%)	87.4% (85.6%; 89.2%)	75.5% (71.1%; 80.1%)	
	II	820	92.5% (90.6%; 94.5%)	85.6% (83.0%; 88.3%)	81.0% (78.0%; 84.1%)	74.8% (71.3%; 78.5%)	69.4% (65.5%; 73.6%)	48.6% (41.1%; 57.5%)	
	III	657	86.0% (83.3%; 88.8%)	75.1% (71.7%; 78.6%)	65.7% (61.9%; 69.8%)	58.3% (54.2%; 62.8%)	50.7% (46.3%; 55.5%)	35.5% (29.5%; 42.6%)	
	IV	1,355	45.2% (42.6%; 48.0%)	31.7% (29.3%; 34.4%)	23.4% (21.1%; 25.9%)	19.2% (17.0%; 21.7%)	16.0% (13.8%; 18.5%)	9.3% (7.1%; 12.2%)	
	X/NA	10,457	53.4% (52.4%; 54.3%)	37.4% (36.5%; 38.4%)	29.0% (28.0%; 29.9%)	23.9% (23.0%; 24.9%)	20.4% (19.4%; 21.3%)	10.7% (9.0%; 12.8%)	
LCC	AII	488	39.0% (34.9%; 43.6%)	27.9% (24.1%; 32.4%)	23.4% (19.8%; 27.8%)	21.8% (18.2%; 26.3%)	21.6% (17.9%; 26.2%)	14.7% (9.1%; 23.7%)	
	I	24	N<50	N<50	N<50	N<50	N<50	N<50	
	II	20	N<50	N<50	N<50	N<50	N<50	N<50	
	III	23	N<50	N<50	N<50	N<50	N<50	N<50	
	IV	48	N<50	N<50	N<50	N<50	N<50	N<50	
	X/NA	373	33.7% (29.2%; 39.0%)	22.1% (18.2%; 27.0%)	18.1% (14.4%; 22.7%)	16.5% (12.9%; 21.2%)	16.5% (12.8%; 21.3%)	8.3% (3.9%; 17.6%)	
Other NSCLC	AII	2,037	67.2% (65.2%; 69.4%)	58.6% (56.4%; 60.8%)	55.2% (52.9%; 57.6%)	52.8% (50.4%; 55.3%)	51.9% (49.4%; 54.6%)	46.8% (42.7%; 51.3%)	
	I	612	99.6% (98.6%; 100.6%)	99.3% (97.8%; 100.8%)	98.1% (96.0%; 100.2%)	96.1% (93.4%; 99.0%)	96.1% (92.9%; 99.3%)	101.0% (94.0%; 108.5%)	
	II	139	93.9% (89.6%; 98.3%)	90.0% (84.4%; 95.9%)	89.4% (83.4%; 95.9%)	87.1% (80.0%; 94.7%)	88.5% (81.4%; 96.3%)	69.9% (53.8%; 90.8%)	
	III	88	85.1% (77.7%; 93.1%)	74.3% (65.4%; 84.5%)	71.2% (61.7%; 82.2%)	68.5% (58.3%; 80.5%)	68.0% (57.5%; 80.5%)	62.1% (46.6%; 82.9%)	
	IV	154	37.5% (30.6%; 46.0%)	26.6% (20.4%; 34.7%)	21.7% (15.9%; 29.6%)	17.7% (12.3%; 25.5%)	16.2% (10.9%; 24.1%)	9.6% (4.1%; 22.7%)	
	X/NA	1,045	47.7% (44.7%; 50.8%)	34.0% (31.1%; 37.1%)	29.2% (26.4%; 32.3%)	26.8% (24.0%; 30.0%)	25.5% (22.5%; 28.8%)	18.6% (14.6%; 23.7%)	
Other	AII	2,840	57.1% (55.2%; 59.0%)	46.6% (44.6%; 48.7%)	40.0% (38.0%; 42.2%)	35.4% (33.2%; 37.7%)	32.4% (30.1%; 34.9%)	16.5% (10.1%; 26.9%)	

Net Survival Probability, 2013-2022								
Type	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	I	1	N<50	N<50	N<50	N<50	N<50	N<50
	II	0	N<50	N<50	N<50	N<50	N<50	N<50
	III	0	N<50	N<50	N<50	N<50	N<50	N<50
	IV	6	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	2,833	57.2% (55.3%; 59.1%)	46.7% (44.7%; 48.8%)	40.1% (38.1%; 42.3%)	35.5% (33.3%; 37.8%)	32.5% (30.2%; 35.0%)	16.5% (10.2%; 26.9%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

4.2.4. Lung cancer survival by histological type, stage and sex: number at risk and net survival probabilities, 2013-2022

Type	Stage	N at risk	Net Survival Probability, 2013-2022						
			1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
Total	All	85,705	53.9% (53.6%; 54.3%)	39.6% (39.3%; 40.0%)	32.7% (32.4%; 33.1%)	28.5% (28.2%; 28.9%)	25.7% (25.4%; 26.1%)	17.1% (16.4%; 17.8%)	
Males									
Lung	All	55,820	51.1% (50.7%; 51.5%)	36.4% (36.0%; 36.8%)	29.6% (29.1%; 30.0%)	25.3% (24.8%; 25.7%)	22.6% (22.2%; 23.0%)	14.4% (13.6%; 15.2%)	
	I	10,469	89.3% (88.6%; 90.0%)	79.0% (78.1%; 80.0%)	70.7% (69.7%; 71.9%)	63.9% (62.7%; 65.1%)	59.2% (57.9%; 60.6%)	39.7% (36.8%; 42.8%)	
	II	4,533	77.7% (76.4%; 79.1%)	62.3% (60.7%; 63.9%)	53.1% (51.4%; 54.8%)	46.4% (44.6%; 48.2%)	42.1% (40.3%; 44.1%)	29.5% (26.6%; 32.9%)	
	III	11,559	60.3% (59.3%; 61.2%)	40.0% (39.0%; 40.9%)	30.3% (29.4%; 31.3%)	24.9% (24.0%; 25.8%)	21.8% (20.8%; 22.7%)	13.3% (11.9%; 14.8%)	
	IV	26,041	29.6% (29.1%; 30.2%)	15.4% (15.0%; 15.9%)	10.5% (10.1%; 10.9%)	8.0% (7.6%; 8.4%)	6.6% (6.2%; 7.0%)	3.2% (2.6%; 3.9%)	
	X/NA	3,703	34.0% (32.5%; 35.6%)	21.5% (20.1%; 22.9%)	16.6% (15.3%; 18.0%)	13.2% (11.9%; 14.5%)	10.6% (9.4%; 11.9%)	3.7% (2.1%; 6.4%)	
SCLC	All	7,617	32.8% (31.7%; 33.9%)	14.0% (13.2%; 14.8%)	9.8% (9.1%; 10.5%)	7.6% (7.0%; 8.3%)	6.7% (6.1%; 7.4%)	3.5% (2.7%; 4.5%)	
	I	237	79.2% (73.8%; 85.0%)	51.6% (45.2%; 59.0%)	40.7% (34.3%; 48.4%)	32.5% (26.2%; 40.4%)	31.1% (24.5%; 39.3%)	18.0% (10.2%; 31.5%)	
	II	232	72.5% (66.7%; 78.9%)	46.3% (40.0%; 53.6%)	39.1% (32.8%; 46.5%)	33.2% (27.1%; 40.7%)	32.0% (25.8%; 39.7%)	12.0% (5.5%; 26.2%)	
	III	1,573	55.8% (53.3%; 58.3%)	29.3% (27.0%; 31.8%)	21.9% (19.8%; 24.2%)	17.2% (15.2%; 19.4%)	14.9% (13.0%; 17.1%)	8.6% (6.3%; 11.9%)	
	IV	4,899	22.9% (21.7%; 24.1%)	6.6% (5.9%; 7.3%)	3.5% (3.0%; 4.1%)	2.5% (2.0%; 3.1%)	2.1% (1.6%; 2.6%)	1.3% (0.8%; 2.1%)	
	X/NA	676	21.5% (18.6%; 24.9%)	7.6% (5.8%; 10.0%)	5.5% (3.9%; 7.6%)	4.1% (2.8%; 6.1%)	3.2% (2.0%; 5.1%)	FU<10y	
NSCLC	All	42,918	54.6% (54.1%; 55.1%)	40.3% (39.8%; 40.8%)	33.1% (32.6%; 33.6%)	28.5% (28.0%; 29.0%)	25.6% (25.1%; 26.1%)	16.8% (16.0%; 17.7%)	
	I	8,146	91.3% (90.6%; 92.0%)	83.0% (82.0%; 84.0%)	75.5% (74.4%; 76.7%)	69.2% (67.9%; 70.6%)	64.8% (63.3%; 66.3%)	45.1% (42.1%; 48.2%)	
	II	3,866	79.9% (78.6%; 81.3%)	65.5% (63.9%; 67.2%)	56.5% (54.7%; 58.4%)	49.7% (47.8%; 51.6%)	44.9% (42.9%; 47.0%)	32.2% (29.0%; 35.8%)	
	III	9,203	63.2% (62.2%; 64.3%)	43.6% (42.5%; 44.7%)	33.2% (32.2%; 34.3%)	27.4% (26.4%; 28.5%)	24.1% (23.1%; 25.3%)	14.7% (13.1%; 16.5%)	
	IV	19,444	33.0% (32.3%; 33.7%)	18.6% (18.0%; 19.2%)	12.9% (12.4%; 13.5%)	9.9% (9.4%; 10.4%)	8.1% (7.7%; 8.6%)	3.9% (3.1%; 4.9%)	
	X/NA	2,524	33.5% (31.7%; 35.5%)	21.4% (19.7%; 23.2%)	15.5% (14.1%; 17.2%)	11.9% (10.5%; 13.5%)	9.4% (8.1%; 11.0%)	3.6% (2.3%; 5.5%)	
SCC	All	15,589	57.7% (56.8%; 58.5%)	41.4% (40.6%; 42.2%)	33.2% (32.3%; 34.0%)	27.9% (27.1%; 28.8%)	24.6% (23.8%; 25.5%)	15.7% (14.5%; 17.1%)	
	I	3,102	87.7% (86.4%; 89.0%)	76.8% (75.1%; 78.6%)	68.0% (66.0%; 70.0%)	59.6% (57.4%; 61.9%)	53.6% (51.2%; 56.0%)	34.5% (30.5%; 39.0%)	

Type	Stage	N at risk	Net Survival Probability, 2013-2022						
			1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
	II	1,926	78.4% (76.4%; 80.4%)	63.4% (61.0%; 65.8%)	53.4% (50.9%; 56.1%)	46.9% (44.3%; 49.8%)	41.5% (38.7%; 44.6%)	32.5% (28.3%; 37.4%)	
	III	4,652	61.0% (59.5%; 62.4%)	40.2% (38.7%; 41.7%)	29.4% (27.9%; 30.9%)	23.5% (22.1%; 25.0%)	20.9% (19.4%; 22.4%)	12.1% (10.3%; 14.2%)	
	IV	4,892	32.3% (31.0%; 33.7%)	15.7% (14.7%; 16.8%)	10.4% (9.5%; 11.4%)	7.8% (6.9%; 8.7%)	6.0% (5.2%; 7.0%)	3.0% (2.0%; 4.7%)	
	X/NA	1,022	34.0% (31.1%; 37.1%)	20.6% (18.1%; 23.4%)	14.8% (12.6%; 17.4%)	11.3% (9.3%; 13.8%)	8.8% (6.9%; 11.2%)	2.4% (1.0%; 5.6%)	
ADC	All	23,436	54.6% (53.9%; 55.3%)	41.3% (40.6%; 41.9%)	34.2% (33.5%; 34.9%)	29.7% (29.0%; 30.4%)	26.9% (26.2%; 27.6%)	17.1% (15.9%; 18.4%)	
	I	4,435	94.0% (93.2%; 94.9%)	87.7% (86.5%; 88.9%)	81.0% (79.5%; 82.5%)	75.7% (74.0%; 77.5%)	71.9% (70.0%; 73.9%)	50.0% (45.6%; 54.9%)	
	II	1,642	83.0% (81.1%; 85.0%)	68.9% (66.5%; 71.4%)	61.2% (58.5%; 64.0%)	53.4% (50.5%; 56.4%)	48.8% (45.8%; 52.0%)	30.0% (24.9%; 36.1%)	
	III	3,768	67.8% (66.2%; 69.4%)	49.0% (47.3%; 50.7%)	38.5% (36.8%; 40.3%)	32.3% (30.6%; 34.1%)	28.3% (26.6%; 30.1%)	17.3% (14.5%; 20.6%)	
	IV	12,517	34.8% (34.0%; 35.7%)	20.6% (19.9%; 21.4%)	14.5% (13.8%; 15.2%)	11.1% (10.5%; 11.8%)	9.2% (8.6%; 9.9%)	4.4% (3.4%; 5.7%)	
	X/NA	1,135	35.5% (32.8%; 38.5%)	23.2% (20.7%; 25.9%)	16.7% (14.5%; 19.3%)	12.4% (10.4%; 14.9%)	9.5% (7.6%; 11.8%)	3.1% (1.7%; 5.8%)	
LCC	All	1,129	33.9% (31.2%; 36.8%)	22.5% (20.1%; 25.3%)	17.8% (15.5%; 20.5%)	14.7% (12.4%; 17.4%)	13.1% (10.7%; 16.0%)	7.1% (4.4%; 11.7%)	
	I	91	84.1% (75.9%; 93.2%)	67.9% (57.6%; 79.9%)	57.0% (46.0%; 70.5%)	51.6% (39.9%; 66.9%)	44.1% (32.2%; 60.4%)	22.0% (10.4%; 46.6%)	
	II	71	75.9% (66.0%; 87.2%)	68.6% (57.7%; 81.7%)	56.9% (44.8%; 72.2%)	56.2% (43.3%; 73.0%)	48.8% (33.9%; 70.2%)	37.8% (17.7%; 80.7%)	
	III	205	50.3% (43.7%; 57.9%)	34.3% (28.1%; 41.9%)	28.0% (21.9%; 35.7%)	22.1% (16.3%; 30.0%)	21.5% (15.6%; 29.7%)	8.4% (3.1%; 23.1%)	
	IV	646	21.0% (18.0%; 24.5%)	10.3% (8.1%; 13.2%)	7.6% (5.6%; 10.3%)	4.1% (2.5%; 6.7%)	3.8% (2.2%; 6.4%)	FU<10y	
	X/NA	116	11.2% (6.7%; 18.9%)	4.5% (1.9%; 10.7%)	1.2% (0.3%; 5.7%)	1.3% (0.3%; 6.1%)	FU<5y	FU<5y	
Other NSCLC	All	3,091	48.2% (46.4%; 50.0%)	36.5% (34.7%; 38.3%)	31.6% (29.8%; 33.4%)	28.7% (26.9%; 30.6%)	27.1% (25.3%; 29.1%)	22.9% (20.2%; 26.0%)	
	I	612	91.5% (88.9%; 94.1%)	82.5% (79.0%; 86.2%)	76.9% (72.8%; 81.2%)	73.3% (68.8%; 78.1%)	72.4% (67.6%; 77.6%)	65.6% (57.2%; 75.2%)	
	II	235	71.5% (65.6%; 77.9%)	57.7% (51.1%; 65.1%)	48.5% (41.5%; 56.7%)	43.7% (36.4%; 52.4%)	44.1% (36.4%; 53.5%)	36.9% (24.7%; 55.1%)	
	III	594	56.4% (52.4%; 60.7%)	38.5% (34.6%; 42.9%)	32.1% (28.2%; 36.5%)	29.2% (25.3%; 33.8%)	24.6% (20.6%; 29.6%)	20.6% (15.5%; 27.3%)	
	IV	1,399	24.7% (22.5%; 27.1%)	14.1% (12.3%; 16.1%)	10.7% (9.1%; 12.6%)	8.4% (6.9%; 10.3%)	7.4% (5.9%; 9.3%)	4.3% (2.5%; 7.2%)	
	X/NA	252	33.2% (27.7%; 39.7%)	24.6% (19.6%; 30.9%)	20.1% (15.4%; 26.3%)	17.1% (12.5%; 23.2%)	15.6% (11.1%; 21.9%)	13.3% (7.6%; 23.5%)	
Other	All	5,591	49.5% (48.1%; 51.0%)	36.9% (35.5%; 38.4%)	29.5% (28.1%; 31.0%)	24.7% (23.2%; 26.3%)	20.9% (19.4%; 22.6%)	10.1% (6.8%; 15.0%)	
	I	2,139	82.8% (81.0%; 84.7%)	66.9% (64.6%; 69.4%)	55.4% (52.7%; 58.2%)	46.3% (43.3%; 49.5%)	39.7% (36.4%; 43.3%)	18.7% (11.8%; 29.6%)	

Net Survival Probability, 2013-2022									
Type	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
	II	442	60.9% (56.0%; 66.1%)	42.1% (37.0%; 47.8%)	30.1% (25.1%; 36.1%)	24.5% (19.4%; 30.8%)	23.3% (17.9%; 30.2%)	13.5% (6.8%; 27.0%)	
	III	795	34.7% (31.3%; 38.4%)	19.8% (16.9%; 23.2%)	13.4% (10.8%; 16.6%)	10.6% (8.0%; 13.9%)	8.0% (5.7%; 11.4%)	6.5% (2.8%; 14.8%)	
	IV	1,712	10.9% (9.5%; 12.6%)	5.2% (4.1%; 6.5%)	2.7% (1.9%; 3.9%)	2.4% (1.7%; 3.6%)	1.6% (0.9%; 2.8%)	0.8% (0.2%; 2.6%)	
	X/NA	507	53.1% (48.7%; 58.0%)	40.1% (35.6%; 45.2%)	36.5% (31.7%; 42.0%)	31.4% (26.5%; 37.2%)	25.9% (20.9%; 32.0%)	10.3% (3.5%; 30.1%)	
Females									
Lung	All	29,885	59.2% (58.6%; 59.8%)	45.6% (45.0%; 46.2%)	38.7% (38.1%; 39.3%)	34.7% (34.0%; 35.3%)	31.6% (31.0%; 32.3%)	22.3% (21.0%; 23.6%)	
	I	6,642	93.3% (92.6%; 94.0%)	86.4% (85.5%; 87.4%)	80.5% (79.4%; 81.7%)	76.2% (74.9%; 77.6%)	72.0% (70.6%; 73.6%)	58.1% (55.0%; 61.3%)	
	II	2,097	82.7% (81.0%; 84.4%)	70.5% (68.4%; 72.7%)	64.0% (61.7%; 66.3%)	57.8% (55.4%; 60.4%)	52.2% (49.6%; 55.1%)	33.3% (27.0%; 41.1%)	
	III	5,493	66.5% (65.2%; 67.8%)	48.1% (46.7%; 49.5%)	38.7% (37.4%; 40.1%)	33.5% (32.1%; 35.0%)	29.8% (28.4%; 31.3%)	18.8% (16.9%; 20.9%)	
	IV	14,104	39.0% (38.2%; 39.8%)	23.6% (22.9%; 24.3%)	17.0% (16.3%; 17.6%)	13.6% (12.9%; 14.2%)	11.5% (10.8%; 12.1%)	5.8% (4.2%; 7.9%)	
	X/NA	1,825	44.1% (41.8%; 46.5%)	32.0% (29.9%; 34.3%)	26.5% (24.4%; 28.8%)	23.5% (21.4%; 25.8%)	21.9% (19.7%; 24.2%)	12.9% (9.7%; 17.1%)	
SCLC	All	4,511	41.9% (40.5%; 43.4%)	22.0% (20.8%; 23.3%)	15.4% (14.3%; 16.5%)	12.2% (11.2%; 13.3%)	10.7% (9.7%; 11.8%)	6.4% (5.2%; 7.8%)	
	I	169	84.7% (79.2%; 90.6%)	63.3% (56.1%; 71.4%)	51.3% (43.8%; 60.2%)	42.9% (35.2%; 52.2%)	40.4% (32.6%; 50.1%)	35.0% (25.7%; 47.6%)	
	II	147	74.5% (67.6%; 82.1%)	54.2% (46.4%; 63.4%)	46.8% (38.7%; 56.5%)	39.3% (31.0%; 49.7%)	34.0% (25.6%; 45.2%)	12.2% (4.3%; 34.5%)	
	III	1,079	63.8% (60.9%; 66.8%)	38.8% (35.9%; 41.9%)	28.3% (25.6%; 31.3%)	22.4% (19.8%; 25.4%)	20.5% (17.9%; 23.4%)	12.0% (8.9%; 16.0%)	
	IV	2,750	30.0% (28.4%; 31.8%)	11.6% (10.5%; 12.9%)	6.8% (5.8%; 7.9%)	5.0% (4.1%; 6.0%)	3.9% (3.2%; 4.9%)	2.6% (1.8%; 3.7%)	
	X/NA	366	34.0% (29.4%; 39.2%)	18.1% (14.5%; 22.6%)	13.0% (9.9%; 17.1%)	11.2% (8.2%; 15.3%)	9.0% (6.3%; 12.9%)	3.7% (1.7%; 7.9%)	
NSCLC	All	22,719	62.9% (62.3%; 63.6%)	50.1% (49.4%; 50.8%)	43.2% (42.5%; 43.9%)	39.0% (38.3%; 39.7%)	35.7% (34.9%; 36.4%)	25.9% (24.7%; 27.3%)	
	I	5,244	95.5% (94.9%; 96.2%)	90.3% (89.3%; 91.2%)	85.4% (84.2%; 86.6%)	82.0% (80.6%; 83.4%)	77.9% (76.3%; 79.5%)	64.5% (61.1%; 68.1%)	
	II	1,754	85.8% (84.1%; 87.6%)	74.7% (72.5%; 76.9%)	68.5% (66.1%; 71.0%)	62.5% (59.9%; 65.3%)	56.3% (53.4%; 59.3%)	36.0% (29.0%; 44.7%)	
	III	4,091	69.5% (68.1%; 71.0%)	52.5% (51.0%; 54.2%)	43.4% (41.8%; 45.1%)	38.1% (36.4%; 39.8%)	33.9% (32.2%; 35.7%)	21.7% (19.4%; 24.3%)	
	IV	10,616	42.9% (42.0%; 43.9%)	27.7% (26.8%; 28.5%)	20.2% (19.4%; 21.0%)	16.2% (15.4%; 17.0%)	13.6% (12.8%; 14.4%)	7.2% (6.1%; 8.4%)	
	X/NA	1,157	42.5% (39.7%; 45.5%)	31.1% (28.4%; 34.0%)	24.9% (22.4%; 27.7%)	21.9% (19.4%; 24.6%)	20.7% (18.2%; 23.6%)	13.7% (10.5%; 17.7%)	
SCC	All	4,223	60.3% (58.8%; 61.8%)	44.8% (43.3%; 46.4%)	37.1% (35.5%; 38.7%)	33.2% (31.7%; 34.9%)	29.5% (27.9%; 31.2%)	18.5% (16.3%; 21.1%)	

Type	Stage	N at risk	Net Survival Probability, 2013-2022						
			1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
	I	960	91.6% (89.7%; 93.6%)	81.3% (78.6%; 84.1%)	72.6% (69.4%; 75.9%)	66.9% (63.4%; 70.6%)	60.2% (56.3%; 64.3%)	38.0% (31.9%; 45.4%)	
	II	471	80.2% (76.5%; 84.0%)	65.7% (61.3%; 70.4%)	58.4% (53.7%; 63.6%)	53.1% (48.1%; 58.6%)	46.1% (40.8%; 52.1%)	30.3% (21.7%; 42.2%)	
	III	1,212	59.3% (56.6%; 62.2%)	39.3% (36.6%; 42.3%)	30.2% (27.6%; 33.1%)	27.0% (24.4%; 29.9%)	23.8% (21.2%; 26.8%)	14.8% (11.4%; 19.0%)	
	IV	1,333	34.7% (32.2%; 37.4%)	19.1% (17.0%; 21.4%)	12.9% (11.1%; 15.0%)	10.3% (8.6%; 12.3%)	8.8% (7.2%; 10.9%)	5.2% (3.2%; 8.5%)	
	X/NA	248	43.2% (37.4%; 50.0%)	29.6% (24.3%; 36.1%)	22.4% (17.5%; 28.7%)	19.4% (14.7%; 25.5%)	17.8% (13.3%; 23.9%)	10.4% (6.0%; 17.8%)	
ADC	All	16,126	64.0% (63.2%; 64.7%)	51.3% (50.5%; 52.1%)	44.0% (43.2%; 44.9%)	39.4% (38.6%; 40.3%)	35.8% (34.9%; 36.7%)	25.6% (24.1%; 27.3%)	
	I	3,558	96.3% (95.6%; 97.1%)	91.6% (90.5%; 92.7%)	87.0% (85.7%; 88.4%)	83.8% (82.2%; 85.4%)	79.7% (77.8%; 81.6%)	66.4% (62.2%; 70.9%)	
	II	1,082	87.8% (85.7%; 89.9%)	78.2% (75.6%; 80.9%)	72.3% (69.3%; 75.4%)	65.9% (62.6%; 69.3%)	58.7% (55.0%; 62.6%)	36.0% (26.4%; 49.0%)	
	III	2,498	75.2% (73.5%; 77.0%)	59.7% (57.7%; 61.8%)	50.3% (48.2%; 52.4%)	43.5% (41.4%; 45.8%)	38.4% (36.2%; 40.8%)	25.1% (22.0%; 28.7%)	
	IV	8,311	45.7% (44.6%; 46.8%)	30.1% (29.1%; 31.1%)	22.0% (21.0%; 23.0%)	17.5% (16.6%; 18.4%)	14.5% (13.6%; 15.5%)	7.4% (6.3%; 8.8%)	
LCC	X/NA	740	43.1% (39.6%; 46.9%)	30.6% (27.3%; 34.3%)	24.1% (21.0%; 27.6%)	20.8% (17.8%; 24.3%)	19.7% (16.7%; 23.3%)	11.0% (7.2%; 16.9%)	
	All	488	39.0% (34.9%; 43.6%)	27.9% (24.1%; 32.4%)	23.4% (19.8%; 27.8%)	21.8% (18.2%; 26.3%)	21.6% (17.9%; 26.2%)	14.7% (9.1%; 23.7%)	
	I	48	N<50	N<50	N<50	N<50	N<50	N<50	
	II	30	N<50	N<50	N<50	N<50	N<50	N<50	
	III	90	63.4% (53.9%; 74.4%)	46.6% (36.9%; 58.9%)	38.9% (29.4%; 51.4%)	35.4% (25.9%; 48.4%)	35.8% (26.2%; 48.9%)	20.4% (9.4%; 44.4%)	
Other NSCLC	IV	277	22.0% (17.6%; 27.5%)	11.9% (8.6%; 16.6%)	8.5% (5.6%; 12.9%)	8.6% (5.7%; 13.1%)	8.7% (5.7%; 13.2%)	FU<10y	
	X/NA	43	N<50	N<50	N<50	N<50	N<50	N<50	
	All	2,037	67.2% (65.2%; 69.4%)	58.6% (56.4%; 60.8%)	55.2% (52.9%; 57.6%)	52.8% (50.4%; 55.3%)	51.9% (49.4%; 54.6%)	46.8% (42.7%; 51.3%)	
	I	742	98.0% (96.7%; 99.4%)	96.4% (94.5%; 98.2%)	94.9% (92.6%; 97.3%)	93.4% (90.5%; 96.3%)	92.3% (88.9%; 95.7%)	91.5% (83.3%; 100.4%)	
	II	175	89.3% (84.5%; 94.3%)	79.2% (72.8%; 86.1%)	75.3% (68.3%; 83.0%)	71.4% (63.7%; 80.2%)	73.5% (65.5%; 82.5%)	61.3% (47.3%; 79.5%)	
Other	III	293	64.9% (59.5%; 70.7%)	47.9% (42.3%; 54.2%)	41.0% (35.4%; 47.6%)	38.7% (32.9%; 45.5%)	37.4% (31.4%; 44.6%)	22.6% (15.0%; 34.0%)	
	IV	700	34.1% (30.8%; 37.9%)	21.4% (18.5%; 24.8%)	17.7% (14.9%; 20.9%)	14.9% (12.2%; 18.0%)	13.5% (11.0%; 16.7%)	8.4% (5.2%; 13.4%)	
	X/NA	127	44.8% (36.9%; 54.6%)	38.8% (31.0%; 48.6%)	35.4% (27.7%; 45.4%)	32.8% (25.0%; 43.0%)	33.4% (25.5%; 43.8%)	33.7% (24.4%; 46.6%)	
	All	2,840	57.1% (55.2%; 59.0%)	46.6% (44.6%; 48.7%)	40.0% (38.0%; 42.2%)	35.4% (33.2%; 37.7%)	32.4% (30.1%; 34.9%)	16.5% (10.1%; 26.9%)	

Net Survival Probability, 2013-2022								
Type	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	I	1,264	85.1% (82.9%; 87.3%)	73.2% (70.4%; 76.1%)	63.4% (60.2%; 66.8%)	55.3% (51.7%; 59.2%)	50.4% (46.4%; 54.6%)	29.7% (22.7%; 38.9%)
	II	197	60.9% (54.0%; 68.6%)	45.5% (38.3%; 54.1%)	36.3% (28.9%; 45.5%)	28.9% (21.2%; 39.3%)	29.7% (21.4%; 41.3%)	26.2% (13.8%; 50.0%)
	III	330	36.9% (31.9%; 42.8%)	22.4% (18.0%; 27.9%)	15.5% (11.6%; 20.8%)	14.4% (10.5%; 19.9%)	9.6% (6.2%; 14.9%)	6.1% (2.5%; 15.4%)
	IV	748	15.5% (13.0%; 18.4%)	10.1% (8.0%; 12.8%)	8.9% (6.8%; 11.7%)	8.9% (6.6%; 12.0%)	9.8% (7.2%; 13.2%)	1.7% (0.3%; 10.8%)
	X/NA	303	62.0% (56.5%; 68.1%)	52.5% (46.7%; 59.1%)	49.1% (43.0%; 56.2%)	45.0% (38.4%; 52.8%)	42.0% (35.0%; 50.5%)	17.3% (7.3%; 40.8%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

5. CANCER SURVIVAL TRENDS



5.1. Lung cancer survival trends: by tumour stage

5.1.1. Lung cancer survival trends by stage and sex: number at risk and net survival probabilities, 2008-2022

Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2008-2012	All	27,911	44.2% (43.6%; 44.8%)	20.8% (20.3%; 21.4%)	15.5% (15.0%; 15.9%)	10,783	51.7% (50.8%; 52.7%)	28.0% (27.1%; 28.9%)	22.3% (21.5%; 23.2%)
	I	4,103	84.3% (83.1%; 85.6%)	63.4% (61.7%; 65.1%)	51.7% (49.9%; 53.7%)	1,804	91.7% (90.3%; 93.1%)	76.4% (74.3%; 78.7%)	67.0% (64.5%; 69.6%)
	II	2,096	69.0% (66.9%; 71.1%)	43.6% (41.4%; 46.0%)	34.6% (32.4%; 37.1%)	665	77.8% (74.6%; 81.2%)	53.8% (49.9%; 58.0%)	46.0% (42.0%; 50.3%)
	III	5,843	53.3% (52.0%; 54.6%)	20.1% (19.0%; 21.2%)	13.0% (12.1%; 14.0%)	2,017	59.0% (56.8%; 61.2%)	27.6% (25.7%; 29.7%)	20.3% (18.6%; 22.3%)
	IV	10,623	25.3% (24.5%; 26.2%)	4.6% (4.2%; 5.0%)	2.3% (2.0%; 2.7%)	4,244	33.4% (32.0%; 34.9%)	8.5% (7.7%; 9.4%)	4.9% (4.2%; 5.6%)
	X/NA	5,335	31.4% (30.2%; 32.7%)	12.4% (11.5%; 13.4%)	8.7% (7.9%; 9.6%)	2,086	39.0% (36.9%; 41.2%)	17.9% (16.3%; 19.8%)	13.6% (12.1%; 15.3%)
2013-2017	All	28,106	47.3% (46.7%; 47.9%)	25.7% (25.1%; 26.2%)	19.6% (19.0%; 20.1%)	13,346	55.7% (54.8%; 56.6%)	34.9% (34.1%; 35.8%)	28.3% (27.5%; 29.2%)
	I	4,779	87.3% (86.2%; 88.4%)	67.9% (66.3%; 69.5%)	57.2% (55.4%; 59.0%)	2,659	93.6% (92.5%; 94.6%)	81.1% (79.3%; 82.8%)	72.3% (70.3%; 74.5%)
	II	2,342	74.5% (72.6%; 76.4%)	48.6% (46.4%; 50.9%)	38.5% (36.2%; 40.9%)	910	78.9% (76.2%; 81.7%)	59.8% (56.4%; 63.3%)	49.1% (45.6%; 52.9%)
	III	5,900	57.1% (55.8%; 58.4%)	26.4% (25.3%; 27.7%)	18.6% (17.5%; 19.8%)	2,476	63.9% (62.0%; 65.9%)	35.2% (33.3%; 37.2%)	26.3% (24.5%; 28.2%)
	IV	12,577	25.5% (24.8%; 26.3%)	7.4% (6.9%; 7.9%)	4.5% (4.2%; 5.0%)	6,140	35.0% (33.8%; 36.2%)	13.1% (12.2%; 14.0%)	8.7% (8.0%; 9.4%)
	X/NA	2,633	32.4% (30.7%; 34.3%)	14.5% (13.1%; 16.0%)	8.6% (7.4%; 9.9%)	1,215	43.5% (40.8%; 46.5%)	25.2% (22.7%; 27.9%)	20.2% (17.8%; 22.9%)
2018-2022	All	27,959	55.1% (54.5%; 55.7%)	33.7% (33.1%; 34.3%)	26.0% (25.2%; 26.7%)	16,691	62.2% (61.4%; 62.9%)	42.0% (41.2%; 42.9%)	34.5% (33.5%; 35.6%)
	I	5,738	90.9% (90.0%; 91.8%)	73.2% (71.7%; 74.7%)	60.6% (58.5%; 62.9%)	4,025	93.2% (92.4%; 94.1%)	80.2% (78.6%; 81.8%)	71.4% (69.1%; 73.8%)
	II	2,196	81.3% (79.5%; 83.1%)	58.4% (55.9%; 61.0%)	46.7% (43.6%; 50.1%)	1,187	85.6% (83.4%; 87.7%)	67.4% (64.3%; 70.6%)	54.6% (50.4%; 59.1%)

Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	III	5,669	63.6% (62.3%; 64.9%)	34.5% (33.1%; 36.0%)	25.8% (24.2%; 27.5%)	3,021	68.5% (66.9%; 70.3%)	41.8% (39.9%; 43.8%)	33.6% (31.4%; 36.0%)
	IV	13,466	33.5% (32.7%; 34.3%)	13.6% (12.9%; 14.2%)	8.7% (8.0%; 9.4%)	7,967	42.0% (41.0%; 43.2%)	20.2% (19.2%; 21.2%)	13.9% (12.9%; 15.0%)
	X/NA	1,071	37.9% (35.0%; 41.0%)	22.4% (19.7%; 25.5%)	18.0% (14.9%; 21.8%)	612	45.2% (41.3%; 49.4%)	29.6% (25.8%; 33.9%)	26.8% (22.5%; 31.9%)

6. CANCER MORTALITY



6.1. Lung cancer mortality: by region

6.1.1. Lung cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Males																						
Belgium	0	0	0	0	1	1	2	4	13	38	98	202	443	592	689	646	538	368	147	16	3,798	74.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[0.5]	[1.1]	[3.5]	[10.0]	[24.6]	[50.1]	[122.0]	[193.2]	[260.0]	[370.8]	[411.8]	[473.7]	[523.6]	[293.4]	[66.9]	(71.6; 76.4)
Brussels	0	0	0	0	1	1	1	0	0	4	7	20	39	33	47	41	30	16	9	0	249	68.6
	[0.0]	[0.0]	[0.0]	[0.0]	[2.6]	[2.0]	[1.9]	[0.0]	[0.0]	[9.2]	[17.5]	[58.6]	[142.7]	[158.8]	[281.4]	[356.6]	[354.9]	[316.6]	[413.8]	[0.0]	[41.6]	(59.9; 77.3)
Flanders	0	0	0	0	0	0	0	2	5	20	48	86	229	317	437	409	349	231	87	10	2,230	69.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.0]	[2.3]	[9.3]	[20.5]	[35.2]	[103.7]	[168.8]	[269.9]	[358.2]	[404.6]	[446.8]	[474.8]	[279.3]	[67.7]	(66.2; 72.0)
Wallonia	0	0	0	0	0	0	1	2	8	14	43	96	175	242	205	196	159	121	51	6	1,319	85.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[1.8]	[7.0]	[11.4]	[34.7]	[76.7]	[152.4]	[247.3]	[237.2]	[403.9]	[442.3]	[577.9]	[673.1]	[426.7]	[73.9]	(80.9; 90.3)
Females																						
Belgium	0	0	0	0	0	0	2	4	13	26	66	132	240	337	347	298	228	143	71	11	1,918	30.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.1]	[3.5]	[7.0]	[17.0]	[33.0]	[64.6]	[103.3]	[117.1]	[139.7]	[123.2]	[105.8]	[107.1]	[57.2]	[32.8]	(29.4; 32.2)
Brussels	0	0	0	0	0	0	0	0	1	3	4	9	21	24	20	25	19	9	3	1	139	28.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.2]	[7.5]	[10.8]	[26.9]	[70.6]	[97.9]	[92.7]	[153.8]	[138.7]	[88.6]	[52.3]	[51.1]	[22.4]	(24.1; 33.8)

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Flanders	0	0	0	0	0	0	1	3	4	11	34	79	120	194	189	169	138	70	43	5	1,060	28.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.4]	[1.9]	[5.2]	[15.0]	[33.0]	[54.4]	[100.5]	[108.6]	[126.8]	[118.8]	[82.4]	[107.2]	[44.5]	[31.6]	(26.5; 30.0)
Wallonia	0	0	0	0	0	0	1	1	8	12	28	44	99	119	138	104	71	64	25	5	719	36.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.9]	[6.9]	[9.8]	[22.6]	[34.5]	[81.8]	[109.5]	[136.9]	[163.2]	[128.7]	[159.8]	[122.4]	[82.8]	[38.6]	(33.5; 38.8)

7. CANCER MORTALITY TRENDS



7.1. Lung cancer mortality trends: by region

7.1.1. Lung cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period				
Belgium	N	4,836	5,036	5,003	4,904	5,008	4,902	4,960	4,868	4,577	4,595	4,601	4,332	4,375	3,969	3,939	3,841	3,673	3,798						
	CR	95.1	98.5	97.3	94.6	95.9	93.0	93.4	90.6	84.5	84.4	84.0	78.7	79.0	71.3	70.4	68.2	64.9	66.9						
	ESR2013		125.9	129.6	125.3	120.6	121.1	115.8	115.4	111.6	102.7	101.2	99.7	92.3	92.1	81.5	80.4	77.1	72.4	74.0	-3.5 (-3.7; -3.2)	2004-2021			
																						-1.9 (-2.8; -1.0)	2004-2010		
																						-4.1 (-5.3; -3.0)	2011-2014		
																							-4.4 (-5.1; -3.7)	2015-2021	
Brussels	N	358	366	353	310	348	332	373	324	301	313	306	281	286	280	236	267	248	249						
	CR	74.5	75.7	72.1	62.4	68.9	64.3	70.8	59.7	54.4	55.7	54.0	49.1	49.3	48.1	40.2	45.1	41.5	41.6						
	ESR2013	111.4	115.8	108.5	95.5	106.8	97.9	113.5	96.5	88.5	90.0	88.1	80.7	81.7	79.5	67.1	73.5	68.5	68.6			-3.1 (-3.7; -2.6)	2004-2021		
Flanders	N	2,836	3,002	2,982	2,990	2,998	2,917	2,948	2,955	2,715	2,725	2,750	2,559	2,599	2,264	2,339	2,274	2,183	2,230						
	CR	95.6	100.7	99.5	99.1	98.6	95.2	95.5	94.9	86.6	86.5	86.9	80.4	81.2	70.3	72.2	69.8	66.5	67.7						
	ESR2013	123.3	127.3	122.9	120.4	118.7	113.2	111.5	109.7	98.8	97.2	96.4	87.7	87.7	74.4	76.3	73.1	68.6	69.1			-3.8 (-4.1; -3.5)	2004-2021		
																							-2.4 (-3.2; -1.6)	2004-2011	
																								-4.8 (-5.3; -4.2)	2012-2021
Wallonia	N	1,642	1,668	1,668	1,604	1,662	1,653	1,639	1,589	1,561	1,557	1,545	1,492	1,490	1,425	1,364	1,300	1,242	1,319						

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
CR	100.1	101.2	100.7	96.2	99.0	97.9	96.4	92.7	90.5	89.8	88.7	85.3	84.8	80.8	77.1	73.2	69.7	73.9		
ESR2013	135.1	138.2	134.3	127.7	129.5	125.4	123.2	118.9	114.1	111.4	108.6	104.0	103.1	96.5	91.3	86.0	80.4	85.6	-3.1 (-3.3; -2.8)	2004-2021
																			-2.1 (-2.7; -1.5)	2004-2012
																			-3.9 (-4.4; -3.4)	2013-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Lung cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period		
Belgium	N	1,282	1,378	1,459	1,499	1,572	1,562	1,753	1,842	1,729	1,885	1,922	1,936	1,950	1,834	1,913	2,008	1,994	1,918			
	CR	24.1	25.8	27.2	27.7	28.9	28.5	31.7	33.0	30.8	33.4	33.9	33.9	34.0	31.9	33.1	34.6	34.2	32.8			
	ESR2013	24.8	26.3	27.6	27.9	29.2	28.6	31.6	32.8	30.5	33.2	33.3	33.2	33.0	30.7	31.4	32.9	32.1	30.8	1.2 (0.9; 1.5)	2004-2021	
																				3.0 (2.4; 3.7)	2004-2013	
																					-0.8 (-1.5; -0.1)	2014-2021
Brussels	N	180	159	179	177	161	171	158	180	165	182	169	176	182	165	145	178	153	139			
	CR	34.6	30.4	33.8	33.1	29.7	31.0	28.1	31.2	28.2	30.7	28.3	29.2	29.9	27.1	23.7	28.9	24.7	22.4			
	ESR2013	38.2	33.7	38.4	36.7	34.0	35.8	32.3	37.2	33.7	37.8	34.9	36.7	36.6	33.9	28.9	35.2	30.4	28.9			
																					-1.0 (-1.7; -0.3)	2004-2021
Flanders	N	620	717	774	789	825	800	923	1,002	888	992	1,016	1,031	1,047	978	1,016	1,118	1,137	1,060			
	CR	20.3	23.4	25.1	25.4	26.4	25.4	29.1	31.4	27.6	30.7	31.3	31.6	32.0	29.7	30.7	33.6	34.0	31.6			
	ESR2013	20.4	23.6	24.9	25.0	25.9	24.8	28.2	30.1	26.6	29.2	29.4	29.7	29.7	27.3	27.9	30.5	30.5	28.3			
																					1.6 (1.1; 2.1)	2004-2021
																					3.5 (2.3; 4.7)	2004-2012
																					0.0 (-1.0; 1.1)	2013-2021
Wallonia	N	482	502	506	533	586	591	672	660	676	711	737	729	721	691	752	712	704	719			
	CR	27.7	28.7	28.8	30.1	33.0	33.1	37.4	36.4	37.1	38.9	40.2	39.6	39.1	37.3	40.6	38.3	37.8	38.6			
	ESR2013	29.1	29.4	29.5	30.7	34.0	33.6	37.5	36.8	36.9	39.1	39.9	38.8	37.9	36.1	38.6	36.7	35.6	36.2			
																					1.4 (1.1; 1.7)	2004-2021
																					3.8 (3.1; 4.4)	2004-2013
																					-1.2 (-1.9; -0.6)	2014-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Recommended reference: Cancer Fact Sheets 2022, Belgian Cancer Registry (BCR), 2024